UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, For Use of the Commission Only (as permitted by 14a-6(e)(2)) | |
| ☒ | Definitive Proxy Statement | |
| ☐ | Definitive Additional Materials | |
| ☐ | Soliciting Material Pursuant To | |
ARROWHEAD PHARMACEUTICALS, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of filing fee (Check the appropriate box):
| ☒ | No fee required. | |||
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid:
| |||
| ☐ | Fee paid previously with preliminary materials. | |||
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing party:
| |||
| (4) | Date filed:
| |||
Notice of Annual Meeting of Stockholders
To Be Held on Thursday, March 19, 202017, 2022
Your vote is important, whether or not you expect to attend the Annual Meeting of Stockholders. Stockholders of record are urged to vote via the Internet or telephone as instructed, or if you are voting by mail, to mark, sign and date and promptly return the proxy in the postage-prepaid return envelope provided.
Voting promptly will help avoid the additional expense of further solicitation to assure a quorum at the meeting.
Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on Thursday, March
You may access the following proxy materials at
• Notice of the
• Company’s
• Company’s Annual Report on Form10-K for the year ended September 30,
• Form of Proxy Card | TO THE STOCKHOLDERS OF ARROWHEAD PHARMACEUTICALS, INC.:
NOTICE IS HEREBY GIVEN that the
1. To elect the
2. To conduct an advisory(non-binding) vote to approve executive compensation;
3. To approve
4. To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 5. To transact any other matters that may properly come before the Annual Meeting or any adjournments or postponements thereof.
The foregoing items of business are more fully described in the Proxy Statement accompanying this Notice. Proposal No. 1 relates solely to the election of the
All stockholders of record are cordially invited to attend the Annual Meeting by visiting www.virtualshareholdermeeting.com/
If you prefer to receive paper copies of our proxy materials, please follow the instructions included in the Notice of Internet Availability. To ensure your representation at the meeting, you are urged to vote via the Internet or telephone as instructed in the Notice of Internet Availability, or to mark, sign, date and return the proxy card as promptly as possible in the postage-prepaid envelope enclosed for that purpose. Any stockholder of record attending the Annual Meeting may vote at the Annual Meeting even if such stockholder has previously returned a proxy. | |||
/s/ Patrick O’Brien Patrick O’Brien Secretary |
Pasadena, California January | |||
Arrowhead Pharmaceuticals, Inc. ● 177 E. Colorado Blvd., Suite 700 ● Pasadena, California 91105
20202022 PROXY STATEMENT Table of Contents
 |
20202022 PROXY STATEMENT General Information Concerning Solicitation and Voting
ARROWHEAD PHARMACEUTICALS, INC.
177 E. Colorado Blvd., Suite 700
Pasadena, California 91105
(626)304-3400
PROXY STATEMENT
FOR ANNUAL MEETING OF STOCKHOLDERS
To be held on Thursday, March 19, 202017, 2022
General Information Concerning Solicitation and Voting
The enclosed Proxy is solicited on behalf of Arrowhead Pharmaceuticals, Inc. (the “Company” or “Arrowhead”) for use at the 20202022 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Thursday, March 19, 202017, 2022 at 10:00 a.m., Pacific time, and at any adjournment(s) or postponement(s) thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders (the “Notice”). This year’s meeting will be a completely “virtual” meeting of stockholders. YouIf you were a stockholder as of the close of business on the Record Date (as defined below), you can attend the Annual Meeting online, vote your shares electronically, and submit your questions and view our list of stockholders as of the Record Date during the Annual Meeting, by visiting www.virtualshareholdermeeting.com/ARWR2020.ARWR2022. You will need to have your16-digit Control Number included on your Notice Regarding the Availability of Proxy Materials (the “Notice“Notice of Internet Availability”Availability”) or your proxy card (if you received a printed copy of the proxy materials) to join the Annual Meeting. If your shares are held in street name and your voting instruction form or Notice of Internet Availability indicates that you may vote those shares through www.proxyvote.com, then you may access, participate in, and vote at the Annual Meeting with the 16-digit access code indicated on that voting instruction form or Notice. Otherwise, stockholders who hold their shares in street name should contact their bank, broker or other nominee (preferably at least five days before the Annual Meeting) and obtain a “legal proxy” in order to be able to attend, participate in or vote at the Annual Meeting.
The meeting webcast will begin promptly at 10:00 a.m. Pacific Time. Online check-in will begin approximately 15 minutes before then and we encourage you to allow ample time for check-in procedures. If you experience technical difficulties during the check-in process or during the meeting, please call the number listed on the meeting website for technical support.
We will endeavor to answer as many stockholder-submitted questions as time permits that comply with the Annual Meeting rules of conduct. We reserve the right to edit profanity or other inappropriate language and to exclude questions regarding topics that are not pertinent to meeting matters or Company business. If we receive substantially similar questions, we may group such questions together and provide a single response to avoid repetition. Additional information regarding the rules and procedures for participating in the Annual Meeting will be set forth in our meeting rules of conduct, which stockholders can view during the meeting at the meeting website.
By hosting the Annual Meeting virtually, we believe we are able to expand access, improve communication and lower costs while reducing the environmental impact of the meeting. This approach also provides for the health and safety of our stockholders and employees in light of the evolving public health and safety considerations posed by the ongoing coronavirus (“COVID-19”) pandemic.
The Company anticipates that the Notice of Internet Availability in connection with these proxy solicitation materials will first be mailed on or about January 28, 202026, 2022 to all stockholders entitled to vote at the Annual Meeting and we will post our proxy materials on the website referenced in the Notice of Internet Availability. As more fully described in the Notice of Internet Availability, all stockholders may choose to access our proxy materials on the website referred to in the Notice of Internet Availability or may request to receive a printed set of our proxy materials.
Only holders of record of our common stock at the close of business on January 22, 202021, 2022 (the “Record Date”) are entitled to notice of the Annual Meeting and to vote at the Annual Meeting. On that date, the Company had outstanding 101,562,158105,448,417 shares of common stock (“Common Stock”).
| 1 |
2022 PROXY STATEMENT General Information Concerning Solicitation and Voting
Any proxy given by a stockholder of record pursuant to this solicitation may be revoked by the person giving it at any time before its use by delivering to the Secretary of the Company, at or before the taking of the vote at the Annual Meeting, a written notice of revocation or a duly executed proxy bearing a later date or by attending the Annual Meeting and voting in person.electronically. Stockholders may also revoke their proxy by entering a new vote over the Internet or by telephone.
Each share of the Company’s Common Stock is entitled to one vote on all matters presented at the Annual Meeting. Each stockholder may appoint only one proxy holder or representative to attend the Annual Meeting on his or her behalf. Stockholders do not have the right to cumulate their votes in the election of directors. Shares of Common Stock represented by properly executed proxies will, unless such proxies have been previously revoked, be voted in accordance with the instructions indicated thereon. In the absence of specific instructions to the contrary, properly executed proxies will be voted FOR the Proposals 1, 2, 3 and 4 and submitted to a vote of stockholders at the Annual Meeting pursuant to this proxy statement. No business other than that set forth in the accompanying Notice of Annual Meeting of Stockholders is expected to come before the Annual Meeting. Should any other matter requiring a vote of stockholders properly arise, the persons named in the enclosed form of proxy will vote such proxy in accordance with the recommendation of the Board of Directors (the “Board”).
If you will not be able to attend the Annual Meeting to vote, in person, you may vote your shares via the Internet or by telephone or by mail as set forth in the Notice.
 |
2020 PROXY STATEMENT General Information Concerning Solicitation and Voting
The Company has engaged a proxy solicitor, Alliance Advisors, LLC, to encourage voting by our stockholders. It is estimated that the total cost for the solicitation campaign will be approximately $10,000. Proxies may also be solicited by certain of the directors, officers and employees of the Company, without additional compensation. The Company will bear the costs of solicitation. In addition, the Company expects to reimburse brokerage firms and other persons representing beneficial owners of shares for their expenses in forwarding solicitation materials to such beneficial owners.
If your shares are held in street name, the voting instruction form sent to you by your broker, bank or other nominee should indicate whether the institution has a process for beneficial holders to provide voting instructions over the Internet or by telephone. If your bank or brokerage firm gives you this opportunity, the voting instructions from the bank or brokerage firm that accompany this proxy statement will tell you how to use the Internet or telephone to direct the vote of shares held in your account. If your voting instruction form does not include Internet or telephone information, please complete and return the voting instruction form in the self-addressed, postage-paid envelope provided by your broker. Stockholders who vote by proxy over the Internet or by telephone need not return a proxy card or voting instruction form by mail.
Quorum; Abstentions; BrokerNon-Votes
The required quorum for the transaction of business at the Annual Meeting is a majority of the votes eligible to be cast by holders of shares of Common Stock issued and outstanding on the Record Date. Shares that are voted “FOR,” “AGAINST” or “ABSTAIN” on a matter are treated as being present at the meeting for purposes of establishing a quorum with respect to such matter. For certain proposals, brokers may not have discretionary authority to vote on a particular matter if they have not received specific instructions from the beneficial owner of the shares (“brokernon-votes”). In accordance with the rules of Nasdaq,the New York Stock Exchange, banks, brokerage firms and other nominees who hold Arrowhead shares in street name for their customers have authority to vote on “routine” proposals when they have not received instructions from beneficial owners. However, banks, brokerage firms and other nominees are precluded from exercising their voting discretion with respect tonon-routine matters. Shares subject to a brokernon-vote will be counted as present for the purpose of determining the presence or absence of a quorum for the transaction of business at the Annual Meeting; the effect of abstentions and brokernon-votes on the proposals presented herein is discussed below.
With regard to the election of directors, votes may be cast in favor of a“FOR,” “AGAINST” or “ABSTAIN” for each director nominee or withheld.nominee. Because directors are elected by plurality,a majority of votes cast in an uncontested election, abstentions from voting and brokernon-votes will be entirely excluded from the vote and will have no effect on its outcome. If a quorum is present at the meeting, the nominees receiving the greatest number ofmore “FOR” votes up to six directors,than “AGAINST” votes will be elected. Abstentions and broker non-votes will be excluded from the vote and will have no effect on its outcome. Because Proposal Nos. 2, 3 and 4 must be approved by the affirmative vote of a majority of the shares of Common Stock entitled to vote thereon and present in person or by proxy at the Annual Meeting (the “Required Vote”), abstentions will be counted in tabulations of the votes cast on each such proposal and will have the same effect as a vote against the proposal, whereas brokernon-votes will be excluded from the vote and will have no effect on its outcome.
| 2 | |
2022 PROXY STATEMENT General Information Concerning Solicitation and Voting
Deadline for Receipt of Stockholder Proposals
Any stockholder who meets the requirements of the proxy rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), who intends to present a proposal at the Company’s 20212023 Annual Meeting of Stockholders must ensure that the proposal is received by the Corporate Secretary at Arrowhead Pharmaceuticals, Inc., 177 E. Colorado Blvd., Suite 700, Pasadena, CA 91105, not later than October 1, 2020,our close of business (5:00 p.m. Pacific Time) on September 28, 2022, in order to be considered for inclusion in our proxy materials for that meeting; provided, however, that if the Company’s 20212023 Annual Meeting of Stockholders is held before February 17, 202115, 2023 or after April 18, 2021,16, 2023, you must provide specified information to us a reasonable time before we begin to print and send our proxy statement for our 20212023 Annual Meeting. Proposals received after the specified dates may be excluded from the Company’s proxy statement.
Additionally, our Amended and Restated Bylaws (“Bylaws”) provide for notice procedures to recommend a person for nomination as a director or to propose business to be considered by stockholders at a meeting. To be considered timely under these provisions, the stockholder’s notice must be received by the Corporate Secretary at our principal executive offices at the address set forth above between 90 and 120 days prior to theone-year anniversary of the date of the 20202022 Annual Meeting;Meeting (between November 17, 2022 and December 17, 2022); provided, however, that if the 20212023 Annual Meeting date is advanced by more than 30 days before or delayed by more than 60 days after the anniversary date of the 20202022 Annual Meeting, then stockholders must provide notice within time periods specified in our Bylaws. Our Bylaws also specify requirements as to the form and content of a stockholder’s notice.
| 3 |
20202022 PROXY STATEMENT Proposal One — Election of Directors
Proposal One — Election of Directors
The Board has nominated the following sixseven persons as directors to serve until the 20212023 Annual Meeting or until their successors have been duly elected and qualified.elected. Each of the nominees is currently a director of Arrowhead. Except as set forth in the biographical information below, none
None of the nominees is related by blood, marriage or adoption to any other nominee or any executive officer of the Company. The six nominees receiving the greatest numbers ofmore “FOR” votes than “AGAINST” votes at the Annual Meeting will be elected to the sixseven director positions. Unless otherwise instructed, the proxy holders will vote the proxies received by them for the sixseven nominees named below. IfUnder Delaware law, a director not receiving a majority of votes cast in an uncontested election would continue to serve as a director as a “holdover director” until the director resigns or is replaced. Under the Company’s director resignation policy, a director who is not reelected by a majority of the votes cast in an uncontested election will be required to tender his or her resignation to the Board, and the Board will then decide whether to accept or reject the resignation, or whether other action is required. Although we have no reason to believe this will occur, if any nominee is unable or declines to serve as director at the time of the Annual Meeting, the proxies will be voted for any nominee who is designated by our present Board to fill the vacancy.vacancy or, alternatively, the Board may reduce its size. The table below sets forth, with respect to each nominee for election, the nominee’s age and current position with Arrowhead. The director nominees have indicated that they are willing and able to serve as directors. However, if any of the director nominees becomes unable or, for good cause, unwilling to serve, proxies may be voted for the election of such other person as shall be designated by our Board, or the Board may decrease the size of the Board.
Nominees for Election as Directors. The Board unanimously adopted a resolution proposing the nominees set forth below for election as directorsDirectors of the Company for the next year.
|
|
|
OUR BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE NOMINEES LISTED BELOW. |
Douglass Given, MD
| ||
Age:
Director since:2010
Serves on: • Nomination Committee • Science Committee
| Experience and Expertise Dr. Given is
Dr. Given has served on more than 20 public and private boards. He is currently a
| |
Qualifications Dr. Given’s qualifications to serve on the Board include his extensive experience as a physician scientist, in finance and business transactions, particularly investments in the life sciences industry, as well as directorship roles in biopharmaceutical companies. Dr. Given also has had significant leadership roles, including CEO of several biotech companies and Senior Vice President, at several large pharmaceutical companies.
| ||
| 4 | |
20202022 PROXY STATEMENT Proposal One — Election of Directors
Michael S. Perry, DVM Independent Lead Director
| ||
Age:
Director since: 2011
Serves on: • Audit Committee • Compensation Committee • Nominating
Other Public Company Boards: • Avita Medical, Inc.
| Experience and Expertise Dr. Perry
| |
Qualifications Dr. Perry’s qualifications to serve on the board include his medical expertise and his extensive experience in preclinical and clinical drug development, including executive level leadership roles and directorships in several publicly held biotech companies.
| ||
Christopher Anzalone, PhD Chief Executive Officer, President & Director
| ||
Age:
Director since: 2007
| Experience & Expertise Dr. Anzalone has been President, Chief Executive Officer and Director of the Company since December 1, 2007 and has led the Company’s business and technical development since then. Prior to joining Arrowhead, Dr. Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Prior to his tenure at the Benet Group, from 1999 until 2003, he was a partner at the Washington,DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr. Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.
| |
Qualifications Dr. Anzalone’s qualifications to serve on the Board include his deep understanding of the business through his role as Chief Executive Officer; in addition, Dr. Anzalone has extensive experience in business development, biotechnology, drug development,
| ||
| 5 |
20202022 PROXY STATEMENT Proposal One — Election of Directors
Marianne De Backer, PhD, MBA Independent Director
| ||
Age:
Director since: 2019
Serves on: •
• Audit Committee • Compensation Committee • Science Committee Other Public Company Boards: • Kronos Bio, Inc.
| Experience & Expertise Dr. De Backer brings over 25 years of experience in healthcare, biotechnology, innovation, strategy, business and corporate development. She has served as member of the Executive Committee, Executive Vice President and Head of Strategy, Business Development and Licensing, and Open Innovation of the pharmaceuticals division of Bayer AG (BAYRY)
| |
Qualifications: Dr. De Backer’s qualifications to serve on the Board include her extensive background in the biopharmaceutical industry, her scientific, drug development, and pharmaceutical transaction experience, as well as her executive leadership experience.
| ||
Mauro Ferrari, PhD Independent Director
| ||
Age:
Director since: 2010
Serves on: • Science Committee (Co-Chair) •Compensation Committee • Nominating Committee
| Experience & Expertise Dr. Ferrari currently serves as Affiliate
| |
Qualifications: Dr. Ferrari’s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology and biomedical applications. Dr. Ferrari has significant technical training, several academic appointments, over
| ||
| 6 | |
20202022 PROXY STATEMENT Proposal One — Election of Directors
Adeoye Olukotun, MD, MPH Independent Director | ||
Age: 77 Director since: 2020 Serves on: • Science Committee (Co-Chair) • Audit Committee • Compensation Committee • Nominating Committee Other Public Company Boards: • Tonix Pharmaceuticals Holding Corp. | Experience & Expertise Dr. Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development , since 2001. Dr. Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr. Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health. | |
Qualifications Dr. Olukotun’s qualifications to serve on the Board include his extensive background in biopharmaceutical development, particularly in the cardiometabolic field, his scientific and public health expertise, and his board and executive leadership experience. | ||
William Waddill Independent Director
| ||
Age:
Director since: 2018
Serves on: • Audit Committee (Chair) • Compensation Committee (Chair) • Nominating Committee
Other Public Company Boards: • Protagonist Therapeutics, Inc. • Annexon Biosciences
| Experience & Expertise Mr. Waddill began his career
| |
Qualifications Mr. Waddill’s qualifications to serve on the Board include his extensive background in the biopharma industry, his financial and audit expertise, executive leadership roles and experience as a director of other public companies.
| ||
| 7 |
20202022 PROXY STATEMENT Proposal One — Election of Directors
Board Composition and Nominating Process
The Nominating Committee of the Board annually considers the size, composition and needs of the Board and, as appropriate, recommends the nominees for directors to the Board for approval. The Nominating Committee considers and evaluates suggestions from many sources regarding possible candidates for directors. Below are general criteria for the evaluation of current and proposed directors:
The highest ethical character and shared values with our Code of Corporate Conduct
Reputation, both personal and professional, consistent with our image and reputation
Accomplishment within candidate’s field, with superior credentials and recognition
Relevant expertise and experience and the ability to offer advice and guidance to the Chief Executive Officer (“CEO”) based on thatsuch expertise and experience
Independence, without the appearance of any conflict in serving as a director,Director, and independence of any particular constituency with the ability to represent all stockholders
Ability to exercise sound business judgment; andjudgment
Diversity, reflecting differences in skills, regional and industry experience, backgrounds, ages, and other unique characteristics, such as race, gender and ethnicity
The Committee believes that the Board should represent a diverse mix of skills, regional and industry experience, backgrounds, ages and other unique characteristics, such as race, gender and ethnicity. In furtherance of this goal, the Committee is committed to actively seeking out highly qualified diverse candidates (including women and minority candidates) to include in the pool from which Board nominees are chosen, referred to by some as the “Rooney Rule.”
Currently, one of the Company’s directors self-identifies as Black and one is a woman. These are the Board’s two most recent additions, demonstrating the Board’s commitment to diversify as it matures. Listed below is a board diversity matrix chart pursuant to the NASDAQ Board Diversity rules.
Board Diversity Matrix (As of December 31, 2021) | ||||||||||||||||
Total Number of Directors | # | |||||||||||||||
| Female | Male | Non-Binary | Did Not Disclose Gender | |||||||||||||
Part I: Gender Identity |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Directors | 1 | 6 | 0 | 0 | ||||||||||||
Part II: Demographic Background |
|
|
|
|
|
|
|
|
|
|
|
| ||||
African American or Black | 0 | 1 | 0 | 0 | ||||||||||||
Alaskan Native or Native American | 0 | 0 | 0 | 0 | ||||||||||||
Asian | 0 | 0 | 0 | 0 | ||||||||||||
Hispanic or Latinx | 0 | 0 | 0 | 0 | ||||||||||||
Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | ||||||||||||
White | 1 | 5 | 0 | 0 | ||||||||||||
Two or More Races or Ethnicities | 0 | 0 | 0 | 0 | ||||||||||||
LGBTQ+ | 0 | |||||||||||||||
Did Not Disclose Demographic Background | 0 | |||||||||||||||
| 8 | |
2022 PROXY STATEMENT Proposal One — Election of Directors
Additionally, the Nominating Committee considers the mix of skills and experience among current and prospective directors with a goal of assembling a Board with complementary skills for the benefit of the Company. Listed below are the relevant skills and attributes present inselected key contributions of each current Boardboard member. The table is not intended to be an exhaustive summary of all the contributions of each board member.
Expertise
|
Given
|
Perry
|
Anzalone
|
De Backer
|
Ferrari
|
Olukotun | Waddill
| Director Tenure
| ||||||||||
Biopharma Research & Development | X |
X |
X |
X |
X |
X | ||||||||||||
Healthcare
|
X |
X |
X |
X | X | |||||||||||||
Drug Development
| X |
X |
X |
X |
X |
X | ||||||||||||
Executive Leadership
|
X |
X |
X |
X |
X |
X | X | |||||||||||
Public Company Governance
| X | X | X | X | X | X | ||||||||||||
Accounting/Audit | X | |||||||||||||||||
Capital Markets | X |
X |
X |
X |
X | |||||||||||||
|
| |||||||||||||||||
|
|
|
X |
X |
X | X | X | |||||||||||
Corporate Governance, PoliciesEnvironmental and PracticesSocial Commitment
The following is a summary of our corporate governance, environmental, and social commitment policies and practices:
Separate Chair and CEO: The positions of Chairman of the Board Chair and CEOChief Executive Officer are separated, which allows our CEOChief Executive Officer to focus on strategic planning and execution as well as ourday-to-day business operations, while allowing the Chairman of the Board Chair to lead the Board in its fundamental role of providing advice to and oversight of management. While our Bylaws do not require that our ChairmanBoard Chair and CEOChief Executive Officer positions be separate, our Board believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.
Majority Independent Board: A majority of the members of the Board are independent directors, as defined by Nasdaq Marketplace Rules. The Board has determined that all of the Company’s directors are independent, except Dr. Anzalone, due to his employment relationship with the Company, and Dr. Given, who is the brother of Bruce Given, the Company’s former Chief Operating Officer.Non-employee directors do not receive consulting or other fees from the Company, other than Board and committeeCommittee compensation.
Independent Lead Director: The Board has appointed an independent Lead Director. The Lead Director is tasked with assuring that the Board committees and other relevant issues have independent leadership.
|
2020 PROXY STATEMENT Proposal One — ElectionBoard Oversight of DirectorsRisk:
The Board has overall responsibility for the oversight of the Company’s risk management process, which is designed to support the achievement of organizational objectives, including strategic objectives, to improve long-term organizational performance and enhance stockholder value. Risk management includes not only understanding company-specific risks and the steps management implements to manage those risks, but also what level of risk is acceptable and appropriate for the Company. Management is responsible for establishing our business strategy, identifying and assessing the related risks and implementing appropriate risk management practices. The Board regularly reviews our business strategy and management’s assessment of the related risk and discusses with management the appropriate level of risk for the Company.
Code of Conduct: All the Company’s employees, officers and directors are subject to the Company’s Code of Business Conduct and Ethics Policy, which is available on the Company’s website at www.arrowheadpharma.com. The ethics policy meets the requirements of Nasdaq Marketplace Rules, as well as the code of ethics requirements of the SEC.
Independent Committees: The Audit Compensation and NominatingCompensation Committees consist entirely of independent directors.
| 9 |
2022 PROXY STATEMENT Proposal One — Election of Directors
Regularly Held Executive Sessions: The independent directors meet separately in executive session on a regular basis to discuss matters relating to the Company and the Board, without members of the management team present.
Board Oversight of Strategy: The Board reviews at least annually the Company’s business initiatives, capital projects and budget matters.
Related Party Transaction Oversight: The Audit Committee reviews and approves all disclosable related-party transactions or, if the size and nature of the transaction warrants, a special committee ofnon-related Board members is formed to negotiate and approve the transaction.
Sustainability: The Company is embarking on an analysis of its environmental impact and ways in which it can operate more responsibly and sustainably. The Company is in the process of building out two research and development facilities, one in Verona, Wisconsin and the other in San Diego, California, and intends both of these facilities to be LEED certified. Additionally, the Company intends to obtain a meaningful percentage of energy used to power these facilities from solar arrays installed on the premises. The Company has been methodically minimizing its use of paper records in favor of electronic records and has a robust recycling program for paper, batteries and electronic equipment.
Human Capital Management: Arrowhead has a vibrant and growing culture and we are committed to the health and welfare of our employees. Our important work developing advanced drugs for patients requires a specialized and dedicated workforce. Arrowhead supports the development of our employees with a generous compensation and benefits package, internal advancement, and individualized development opportunities. We are committed to training young scientists and businesspeople and offer multiple internships and entry level positions each year. Arrowhead was voted one of the “Best Places to Work” among our small pharma peers by BioSpace, a life sciences industry hub for news and careers. Our annual voluntary turnover rate has been less than 8% for the last 3 fiscal years and our annual internal promotion rate has ranged from 10-15% annually.
Workforce Diversity: As of December 31, 2021, women comprise 45% of our employee workforce and 34% of our employee leaders at the level of director or above. People self-identifying as racial and ethnic minorities comprise 33% of our employee workforce and 34% of our employee leaders at the level of director or above. One of our executive officers is a member of the LGBTQ+ community.
Corporate Responsibility: Arrowhead is also committed to the communities in which we operate. The Company and our employees participate in multiple charitable outreach events each year, and in 2022 expect to establish a scholarship fund intended to foster scientific education for minority students.
Stockholder Communications with Directors
Stockholders who wish to communicate with the Board or any individual director can write to: Patrick O’Brien, Corporate Secretary, Arrowhead Pharmaceuticals, Inc.,177, 177 E. Colorado, Suite 700, Pasadena, CA 91105. Your letter should indicate that you are an Arrowhead stockholder. Depending on the subject matter, management will:
Forward the communication to the director or directors to whom it is addressed;
Forward the communication to the Chairman of the Board Chair, if addressed to the Board;board of directors; or
If not addressed to, or otherwise appropriate for, any director or directors, attempt to handle the inquiry directly (for example, requests for information or stock-related matters).
The Board held a total of foursix meetings during the fiscal year ended September 30, 2019.2021. The Board has three standing committees: Audit Committee, Compensation Committee and Nominating Committee.
The functions of the Audit Committee are to select and oversee the independent registered public accountants,accounting firm, to review the scope and results of theyear-end audit with management and the independent auditors, to review the Company’s accounting principles and its system of internal accounting controls, to review the Company’s annual and quarterly reports before filing with the Securities and Exchange Commission (“SEC”) and to review any related-party transactions. The Audit Committee met four times during fiscal 2019.2021. The current members of the Audit Committee are William Waddill, Chairman,Committee Chair, Marianne De Backer, Mauro Ferrari, Adeoye Olukotun, and Michael S. Perry. The Board has determined that all members of the Audit Committee who served during 20192021 were independent directors under the rules of the SEC and the listing standards of Nasdaq Marketplace Rules and are financially literate. The Board has determined that Mr. Waddill is an “audit committee financial expert” in accordance with the applicable regulations, based on his experience as noted above. The Audit Committee Charter is available on the Company’s website at www.arrowheadpharma.com.
| 10 | |
2022 PROXY STATEMENT Proposal One — Election of Directors
The functions of the Compensation Committee are to review the goals and achievements of the Company and the Chief Executive Officer for the prior year and approve the goals of the Company and the Chief Executive Officer for the next year, to review and approve salaries, bonuses, equity awards and other benefits payable to the Company’s executive officers and to administer the Company’s 2004 Equity Incentive Plan and 2013 Incentive Plan.equity incentive compensation plans. The Compensation Committee is specifically responsible for determining the compensation of the Chief Executive Officer and the other executive officers. The Compensation Committee reviews compensation recommendations made by the Chief Executive Officer for other senior executives of the Company and the compensation of the Chief Executive Officer at least annually; the Chief Executive Officer is not present during discussions or deliberations regarding his compensation. In fiscal 2019,2021, the Compensation Committee engaged Compensia, Inc., a compensation consulting firm, to provide advice and guidance with regard to compensation for our named executive officers.NEOs. The decision to engage the consultant was not made or recommended by management and the Compensation Committee has the sole discretion to engage or change the consultant. The Compensation Committee met
|
2020 PROXY STATEMENT Proposal One — Election of Directors
three times during fiscal 2019.2021. The current members of the Compensation Committee are Michael S. Perry, Chairman,William Waddill, Committee Chair, Marianne De Backer, Mauro Ferrari, William WaddillAdeoye Olukotun, and Marianne De Backer.Michael Perry. The Board has determined that all members of the Compensation Committee are independent directors under the listing rules of Nasdaq Marketplace Rules. The Compensation Committee’s charter is available on the Company’s website at www.arrowheadpharma.com. The Compensation Committee has not delegated any of its responsibilities or authorities granted under its charter.
The Nominating Committee is responsible for proposing a slate of directors for election by the stockholders at each Annual Stockholders Meetingannual meeting and for proposing candidates to fill any vacancies. The Nominating Committee met oncethree times during fiscal 2019.2021. The current members of the Nominating Committee are Michael S. Perry, Chairman, Marianne De Backer, Committee Chair, Mauro Ferrari, Douglass Given, Adeoye Olukotun, Michael Perry and William Waddill. For as long as Dr. Given does not meet independence criteria nominations are made by a majority of the independent directors without the participation of Dr. Given. The Nominating Committee’s charter is available on the Company’s website at www.arrowheadpharma.com. The Nominating Committee manages the process for evaluating current Board members at the time they are considered forre-nomination. After considering the appropriate skills and characteristics required on the Board, the current makeup of the Board, the results of the evaluations and the wishes of the Board members to bere-nominated, the Nominating Committee recommends to the Board whether those individuals should bere-nominated.
On at least an annual basis, the Nominating Committee reviews with the Board whether it believes the Board would benefit from adding new members and, if so, the appropriate skills and characteristics required for any new members. If the Board determines that a new member would be beneficial, the Nominating Committee solicits and receives recommendations for candidates and manages the process for evaluating candidates. All potential candidates, regardless of their source, are reviewed under the same process. The Nominating Committee (or its chairman)the Committee Chair) screens the available information about the potential candidate(s). Based on the results of the initial screening, interviews with candidates are scheduled with Nominating Committee members, other members of the Board and senior members of management. Upon completion of these interviews and other due diligence, the Nominating Committee may nominate a candidate to the Board for election.
Candidates for independent Board member positions are identified through recommendations from directors or others associated with the Company, as well as through a formal search process managed by an executive recruiter.a third-party search firm. Arrowhead stockholders may also recommend candidates by sending the candidate’s name and resume to the Nominating Committee pursuant to the procedures, set forth above, for communication with the Board. As described above, our Bylaws also provide for separate notice procedures to recommend a person for nomination as a director to be considered by stockholders at a meeting, including requirements as to the timing, form and content of a stockholder’s notice.
The Nominating Committee has no predefined minimum criteria for selecting Board nominees, although it believes that all directors should share qualities such as governance and business experience at the corporate level, relevantnon-competitive experience and strong communication and analytical skills. Independent directors must meet the criteria for independence set forth by Nasdaq and, as applicable, the SEC. In any given search, the Nominating Committee may also define particular characteristics for candidates to balance the overall mix of skills, backgrounds and characteristics of the Board and the needs of the Company. During any search, the Nominating Committee reserves the right to modify its stated search criteria for exceptional candidates.
As part of the Nominating Committee’s goal of building a diverse board, the Nominating Committee is committed to actively seeking out highly qualified diverse candidates (including women and minority candidates) to include in the pool from which Board nominees are chosen. The Nominating Committee assesses its effectiveness in achieving thisits goal of building a diverse board as part of its annual assessment of the composition of the Board.
In 2018, the Board established an ad hoca Science Committee to review and advise on science topics of interest to the Company. The current members of the committee are Mauro Ferrari, Chairman,Committee Co-Chair, Adeoye Olukotun, Committee Co-Chair, Douglass Given, and Michael S. Perry.Marianne De Backer.
| 11 |
2022 PROXY STATEMENT Proposal One — Election of Directors
No incumbent director attended fewer than 75% of the aggregate of (i) the total number of meetings of the Board held during fiscal 2019,2021, and (ii) the total number of meetings held by all committees of the Board during fiscal 20192021 on which such person served.served, in each case during the period in which such person served on the Board or committee.
In addition, all of the directors then serving on the Board attended the virtual 20192021 Annual Meeting of Stockholders. It is the Company’s policy to encourage, but not require, that all directors attend our annual stockholder meetings.
| 12 | |
20202022 PROXY STATEMENT Director Compensation
Directors who are also employees of the Company receive no separate compensation from the Company for their service as members of the Board. For 2020,2021, the Company maintained the structure of director compensation that wasit adopted in 2019 to provide a base retainer for each director with higher base retainers for service by the Chairman of the Board Chair and the Lead Independent Director. The Company provides additional retainers for committee service with higher retainers for committee leadership. The Compensation Committee believes the structure aligns compensation according to specific leadership and committee service contributions by each director. Year over year, total director compensation increased modestly in 2020 to reflect the increased demands and complexity as the Company adds to and advances our pipeline.
The below table sets forth compensation levels for each of our outside directors for calendar 2019 and 2020.
| Name & Position | 2020 Annual (effective | 2020 Stock Award (2) | 2020 Grant Date Value | 2019 Annual Fee (3) (effective 1/1/19) | 2019 Stock Award (2) | 2019 Grant Date Value | ||||||||||||||||||
Douglass Given Chairman
| $
| 85,000
|
|
| 8,000
|
| $
| 507,440
|
| $
| 80,000
|
|
| 36,000
|
| $
| 447,120
|
| ||||||
Michael S. Perry Lead Director
| $
| 80,000
|
|
| 8,000
|
| $
| 507,440
|
| $
| 80,000
|
|
| 36,000
|
| $
| 447,120
|
| ||||||
Mauro Ferrari Director (4)
| $
| 120,000
|
|
| 7,500
|
| $
| 475,725
|
| $
| 135,556
|
|
| 8,429
|
| $
| 194,738
|
| ||||||
William Waddill Director
| $
| 75,000
|
|
| 7,500
|
| $
| 475,725
|
| $
| 70,000
|
|
| 30,000
|
| $
| 372,600
|
| ||||||
Marianne De Backer Director (5)
| $
| 70,000
|
|
| 7,500
|
| $
| 475,725
|
| $
| 0
|
|
| 5,000
|
| $
| 336,600
|
| ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020 PROXY STATEMENT Director Compensation
The following table sets forth the total compensation paid to ournon-employee directors in fiscal 2019.2021. Dr. Anzalone’s compensation is set forth in the discussion of Executive Compensation and in the Summary Compensation Table.
| Name
| Fee Earned
| Stock
| Total ($)
| Fee Earned or Paid in Cash ($) | Stock Awards ($) (1) (2) | Total ($) | |||||||||||||||||||||
Douglass Given
| $
| 78,438
|
| $
| 447,120
|
| $
| 525,558
|
| ||||||||||||||||||
Douglass Given (3) | $ | 185,000 | $ | 728,935 | $ | 913,935 | |||||||||||||||||||||
Michael S. Perry
| $
| 75,813
|
| $
| 447,120
|
| $
| 522,933
|
| $ | 80,000 | $ | 690,570 | $ | 770,570 | ||||||||||||
Mauro Ferrari (3)
| $
| 107,431
|
| $
| 194,738
|
| $
| 302,169
|
| ||||||||||||||||||
Mauro Ferrari | $ | 73,750 | $ | 690,570 | $ | 764,320 | |||||||||||||||||||||
William Waddill
| $
| 64,375
|
| $
| 372,600
|
| $
| 436,975
|
| $ | 78,750 | $ | 690,570 | $ | 769,320 | ||||||||||||
Marianne De Backer (4)
|
| N/A
|
|
| N/A
|
|
| N/A
|
| ||||||||||||||||||
Marianne De Backer | $ | 73,750 | $ | 690,570 | $ | 764,320 | |||||||||||||||||||||
Adeoye Olukotun | $ | 75,000 | $ | 690,570 | $ | 765,570 | |||||||||||||||||||||
| (1) | This column represents the total grant date fair value, computed in accordance with ASC 718, of restricted stock units granted during fiscal year |
| (2) | The RSUs granted tonon-employee directors vest one year from the date of grant. |
| (3) | Dr. |
|
As of the last day of fiscal year 2019,2021, the directors held the following outstanding stock option and restricted stock unit grants in the aggregate: Douglass Given — 36,0009,500 restricted stock units; Michael S. Perry — 77,000 stock options and 36,0009,000 restricted stock units; Mauro Ferrari — 20,0009,000 restricted stock options and 5,000units; William Waddill — 9,000 restricted stock units; Marianne De Backer — 9,000 restricted stock units; and William WaddillAdeoye Olukoton — 30,0009,000 restricted stock units.
Vote Required; Recommendation of the Board
The six nominees listed above receiving the greatest numbers ofmore “FOR” votes at the meeting,than “AGAINST” votes, assuming a quorum is present, will be elected to the six director positionstas directors to serve until their terms expire or until their successors have been duly elected and qualified. Because directors are elected by plurality,a majority of votes cast, abstentions from voting and brokernon-votes will be entirely excluded from the vote and will have no effect on its outcome.
|
|
|
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL ONE.
|
|
20202022 PROXY STATEMENT Proposal Two — Advisory Vote to Approve Executive Compensation
Proposal Two — Advisory Vote to Approve Executive Compensation
The compensation paid to our Named Executive Officers (“NEOs”) is described below in the Compensation Discussion and Analysis of this proxy statement for the year ended September 30, 2019.2021. The Board is asking stockholders to cast anon-binding, advisory vote FOR the following resolution:
“RESOLVED, that the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of RegulationS-K, as set forth in the compensation tables and narrative discussion, is hereby APPROVED.”
Although the vote we are asking you to cast isnon-binding, the Compensation Committee and the Board value the views of our stockholders and will consider the outcome of the vote when determining future compensation arrangements for our named executive officers.NEOs.
The Board has adopted a policy providing for annual advisory votes to approve executive compensation. Unless the Board modifies its policy on the frequency of holding advisory votes to approve executive compensation, the next such advisory vote will occur in 2021.2023.
Vote Required; Recommendation of the Board
Proposal Two must be approved by the Required Vote, assuming a quorum is present. For this purpose, abstentions will be counted as a vote against the proposal, while brokernon-votes will have no effect on the outcome of the vote.
|
|
|
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL TWO. |
|
20202022 PROXY STATEMENT Proposal Three — Amendment to Bylaws to Elect Directors by a Majority VoteApproval of the Arrowhead Pharmaceuticals, Inc. Non-Employee Director Compensation Plan
Proposal Three — Amendment to Bylaws to Elect Directors by a Majority VoteApproval of the Arrowhead Pharmaceuticals, Inc. Non-Employee Director Compensation Plan
Background Regarding Requested Stockholder Action
In February 2021, a derivative action was brought in the Court of Chancery in Delaware, suing our directors, purportedly on behalf of us, for damages as a result of their alleged breaches of their fiduciary duties by granting and accepting allegedly excessive and unfair compensation in each of 2019, 2020, and 2021.
In late 2021, the plaintiffs and the director defendants negotiated the terms of a settlement that requires us, among other things, to limit non-employee director compensation for a five year period to the 60th percentile of the mean per-director compensation package paid by our peer companies. In this Proposal 3,Three, we are asking stockholders to approve an amendment and restatementseeking stockholder approval of our current Bylaws to implementnon-employee director compensation plan in a majority voting standard formanner consistent with the election of directors in uncontested elections. Our current Bylaws provide for a plurality voting standing, pursuant to which the director nominees who receive a plurality of votes in an election for directors are elected whether or not they receive a majorityterms of the votes cast. In responsesettlement.
The director defendants have vigorously denied, and continue to suggestions by our stockholdersvigorously deny, all allegations of wrongdoing, fault, liability or cognizable damage to the Company, and believe that they acted properly at all times. The director defendants agreed to the settlement solely because they deemed it desirable that the claims against them in fiscal year 2019, the action be settled and dismissed with prejudice in order to, among other things, (i) avoid the substantial expense, inconvenience and distraction of continued litigation, and (ii) avoid any possibility of a finding of liability, however remote, and finally put to rest the claims asserted against them.
Requested Stockholder Approval
The Board has determined itbelieves that stockholder approval of the non-employee director compensation plan included as Exhibit A to this proxy statement (the “Plan”) is in the best interests of the Company and our stockholders because it allows us to attract and has adopted, subjectretain highly qualified non-employee directors, which we believe is critical to our long-term success. We believe that the compensation proposed to be paid to non-employee directors pursuant to the Plan is reasonable and appropriate and in line with market practice, appropriately compensates our non-employee directors for services as non-employee directors, and aligns the interests of non-employee directors with those of the Company and our stockholders. We are asking our stockholders to approve the Plan which, if approved, shall continue to apply until otherwise modified by our Board. If the Plan is not approved by our stockholders, we will not provide our non-employee directors with compensation under the Plan until such time, if any, as stockholder approval of a subsequent similar proposal is obtained, and instead will compensate our non-employee directors in the manner outlined in the settlement and described above. We believe this will have an amendmentadverse effect on our ability to attract and restatementretain qualified directors to our board of directors.
Summary of the Plan
The purpose of the Plan is to provide a compensation package that enables the Company to attract and retain high-caliber directors and aligns their interests with the interests of the Company’s stockholders.
Eligibility
The Plan apples to all members of the Board who are not employees or officers of the Company. All six of our Bylawscurrent non-employee directors are eligible to provide that in an uncontested election of directors, each director must receive more “For” votes than “Withheld” votes to be elected. In any contested elections of directors, where there are two or more nominees for a board position,compensation under the election will continue to be decided by plurality vote.Plan.
Director Pay Limit
Under existing Delaware law,the Plan, on an annual basis, the Compensation Committee’s independent compensation consultant will conduct an analysis on non-employee director compensation practices at a director not receivinggroup of peer companies, including an assessment of the mean per-director annual compensation package paid by each peer company. The list of peer companies will be approved annually and will include at least fifteen companies that are appropriate peers for the Company’s size (e.g., market capitalization, revenue, employee count) and competitive environment for directors. In general, the value of the mean per-director compensation paid under the Plan each year cannot exceed the mean per-director compensation package paid by the peer company representing the 60th percentile; provided, however, that if a majority of votesstockholders approve this Proposal Three, then if, in an uncontested election would continue to serveany year, the Company’s 3-year total stockholder return (TSR) as a director as a “holdover director” untilcalculated by the director resigns or is replaced. The amendment and restatement also provides for a director resignation policy under which a director who is not reelected by a majorityCompensation Committee’s independent compensation consultant exceeds the 3-year TSR of the votes cast in an uncontested election will be required to tender his or her resignation topeer company representing the Board, and the Board will then decide whether to accept or reject the resignation, or whether other action is required. Under the policy, a director who is proposed for reelection and who does not receive a majority of the votes cast will not automatically remain on the Board as a holdover director. Rather, his or her continued service as a director will be subject to review by the Board, taking into account the stockholders’ vote and any other relevant considerations.60th
The foregoing is a summary of the proposed amendment of our Bylaws, which is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws as set forth in Exhibit A (with additions shown as underlined and deletions shown as struck through).
The Board is asking stockholders to cast a vote FOR the following resolution:
“RESOLVED, that the stockholders of the Company approve the Amended and Restated Bylaws in a form substantially as provided in Exhibit A to this Proxy Statement.”
|
|
|
20202022 PROXY STATEMENT Proposal Three — Approval of the Arrowhead Pharmaceuticals, Inc. Non-Employee Director Compensation Plan
percentile when ranked by 3-year TSR, the non-employee director pay limit described in this paragraph for the next following year will be increased to correspond to the mean per-director compensation package paid by the peer company representing the percentile of the mean per-director compensation package paid by each of the peer companies that is equivalent to the percentile rank of the Company relative to the peer companies when ranked by 3-year TSR for such prior year. For fiscal year 2022, because the Company’s 3-year TSR for fiscal year 2021 ranks at the 95th percentile of the Company’s 2021 peer group the mean per-director compensation paid under the Plan, if approved will not exceed $782,956.
Cash and Equity Retainers
On an annual basis, the Board, with the assistance of the Compensation Committee, will determine the value of cash and equity retainers paid to the non-employee members of the Board, which need not be the same for every director and which may take into account service as non-executive chair or lead independent director and/or service as chair or as a member on one or more committees of the Board; provided that the mean per-director compensation shall not exceed the limit on such compensation as determined in accordance with the procedures described above under the section titled Director Pay Limit. For fiscal year 2022, the cash and equity retainers consist of $475,700 in average value per non-executive director unless the Plan is approved.
Non-Employee Director Compensation Plan Benefits
Except for our non-employee directors, no other person is eligible to participate in the Plan. While the compensation to be paid under the Plan will be made in accordance with the terms described above, the specific amounts that will be received by our non-employee directors under the Plan will depend on a number of factors, including the annual determination of the non-employee director compensation limit, and, with respect to the equity component, the market price of our common stock.
The average cash and equity compensation that will be paid to our current non-employee directors for their period of service in 2022 if the Plan is approved, to the extent ascertainable, is $782,956.
Certain Interests of Directors
In considering the recommendation of the Board with respect to this Proposal Three, stockholders should be aware that certain of our non-employee directors have certain interests, which may present them with conflicts of interest in connection with this proposal.
Vote Required; Recommendation of the Board
Proposal Three must be approved by the Required Vote, assuming a quorum is present. For this purpose, abstentions will be counted as a vote against the proposal, while broker non-votes will have no effect on the outcome of the vote.
| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” PROPOSAL THREE. |
| 16 | |
2022 PROXY STATEMENT Executive Compensation
COMPENSATION DISCUSSION AND ANALYSIS
The following compensation discussion and analysis contains statements regarding future individual and Company performance targets and goals. These targets and goals are disclosed in the limited context of Arrowhead’s executive compensation programsprogram and should not be understood to be statements of management’s expectations or guidance. Arrowhead cautions investors not to apply these statements to other contexts. Fiscal years are denoted as fiscal years, all other year references refer to calendar years.
This Compensation Discussion and Analysis describes the compensation program for our Named Executive Officers.Officers (our “NEOs”). During fiscal year 2019,2021, these individuals were:
Christopher Anzalone, our President and CEO;
Bruce D. Given, our Chief OperatingExecutive Officer (our “COOCEO”);
Kenneth Myszkowski, our Chief Financial Officer (our “CFO”);
Patrick O’Brien, our General Counsel, Corporate Secretary, and Chief Compliance Officer (our “GC”);
Javier San Martin, our Chief Medical Officer (our “CMO”);
James Hamilton, our Senior Vice-President, Discovery and Translational Medicine; and
Zhen Li,James Hassard, our former Senior Vice President, Chemistry &Non-Clinical DevelopmentChief Commercial Officer (our “SVPCCO”).
This Compensation Discussion and Analysis describes the material elements of our executive compensation program during 2019.fiscal 2021. It also provides an overview of our executive compensation philosophy and objectives and summarizes our executive compensation policies and practices. Finally, it analyzes how and why the Compensation Committee of our Board of Directors (the “Compensation Committee”) arrived at the specific compensation decisions for our executive officers, including our Named Executive OfficersNEOs, for 2019fiscal 2021 including the key factors that the Compensation Committee considered in determining their compensation.
We develop medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics.
20192021 Business Highlights
Began dosingExecuted an agreement with GlaxoSmithKline (“GSK”) under which GSK will develop and commercialize ARO-HSD, being developed as a treatment for patients with alcohol-related and non-alcohol related liver diseases, such as nonalcoholic steatohepatitis, which includes a $120 million upfront payment, $320 million in a Phase 1 singlepotential development milestones, $590 million in potential sales-related milestones and multiple dose study oftiered royalties on net product sales.
Executed and closed an agreement with Horizon Therapeutics (“Horizon”) under which Arrowhead and Horizon will collaborate to develop ARO-ANG3,ARO-XDH, a subcutaneously administered RNAi therapeutic targeting angiopoietin like protein 3, being developed as a treatment for patients with uncontrolled gout, which included a $40 million upfront payment, $660 in potential development, regulatory and commercial milestones and royalties in the low-to-mid-teens on net product sales.
Janssen Pharmaceuticals, Inc. (“Janssen”) disclosed that it is collaborating with Arrowhead on JNJ-75220795, being developed to reduce expression in the liver of patatin like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with dyslipidemiasnon-alcoholic steatohepatitis (“NASH”). Earned a $10 million option exercise fee from Janssen in connection with Janssen’s option to develop and metabolic diseases;
Began dosingcommercialize JNJ-75220795, and a further $10 million milestone payment from Janssen after Janssen dosed the fifth patient in a Phase 1 single and multiple doseclinical study ofARO-APOC3,JNJ-75220795. a subcutaneously administered RNAi therapeutic targeting apolipoproteinC-III, being developed as a potential treatment for patients with hypertriglyceridemia;
Expanded the AROHBV1001 Phase 1/2 study to include a new triple combination cohort (cohort 12) that includesJNJ-3989 and additional undisclosed agents selected by Arrowhead’s partner, Janssen Pharmaceuticals, Inc.;
Began dosing patients in an adaptive design Phase 2/3 trial, called SEQUOIA, with the potential to serve as a pivotal registrational study ofARO-AAT, Arrowhead’s second generation subcutaneously administered RNAi therapeutic being developed as a treatment for a rare genetic liver disease associated withalpha-1 antitrypsin deficiency;
Presented new clinical data on our two cardiometabolic candidates,ARO-APOC3 andARO-ANG3, in two late-breaking oral presentations at the American Heart Association Scientific Sessions 2019);
| 17 |
20202022 PROXY STATEMENT Executive Compensation
Was granted Breakthrough Therapy Designation by the FDA for ARO-AAT, being developed for the treatment of the rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
In April 2019,Reported interim results on ARO-AAT, ARO-APOC3, being developed for the Company earnedtreatment of patients with hypertriglyceridemia, severe hypertriglyceridemia and familial chylomicronemia syndrome, ARO-HSD, and ARO-HIF2, being developed as a $25 million milestone payment from Janssen followingtreatment for patients with clear cell renal cell carcinoma.
Presented pre-clinical data on ARO-DUX4, Arrowhead’s first muscle-targeted investigational RNAi therapeutic candidate which is being developed as a treatment for facioscapulohumeral muscular dystrophy, which data suggests that ARO-DUX4 achieved good target engagement which led to a downstream beneficial physiological change, and which may support advancement into clinical studies.
Dosed the initiationfirst patient in AROAPOC3-2001, a Phase 2b clinical study of dosingARO-APOC3 in adults with severe hypertriglyceridemia, and the triple combination cohort (cohort 12)first patient in the Company’s ongoingAROAPOC3-2002, a Phase 1 / 22b clinical study ofJNJ-3989(ARO-HBV).ARO-APOC3 In August 2019,in adults with mixed dyslipidemia.
Dosed the Company earned an additional $25 million milestone payment from Janssen following the initiation of dosingfirst patient in its phaseAROANG3-2001, a Phase 2b clinical study ofJNJ-3989(ARO-HBV);ARO-ANG3, being developed as a treatment for patients with mixed dyslipidemia.
Filed an application for clearance to begin Phase 1/2a clinical trials of ARO-C3.
In December 2019,Executed and closed on the Company closed an underwritten public offeringacquisition of 13.06 acres of land in Verona, Wisconsin which we intend to use to construct a manufacturing facility and received gross proceeds of $266.8 million, before deducting underwriting discounts, commissionsrelated process development and other offering expenses;analytical laboratories.
Ended calendar 2019fiscal 2021 with $528$613 million in cash and investments; and
Achieved 47% total stockholder return (“TSR”) in fiscal 2019.
| • | Achieved a three-year total stockholder return (“TSR”) at the 100th percentile of our peer group as measured in November 2020. |
Janssen Pharmaceuticals, Inc.GlaxoSmithKline
In October 2018, weNovember 2021, Arrowhead entered into aan exclusive license agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson,GSK to develop and commercializeARO-HBV.ARO-HSD, In addition, we entered into a research collaboration and option agreement with JanssenPhase 2 investigational therapy in development to potentially collaborate for up to three additional RNAi therapeutics against new targets to be selected by Janssen.treat NASH.
Under the terms of the agreement, GSK has the exclusive right to develop, obtain regulatory approval for and commercialize ARO-HSD. Arrowhead is eligible to receive a $120 million upfront payment, $320 million in potential development milestones, $590 million in potential sales-related milestones and tiered royalties on net product sales.
Horizon
In June 2021, Arrowhead entered into a global collaboration and license agreement wewith Horizon to develop and commercialize ARO-XDH, a discovery-stage therapy in development to treat uncontrolled gout.
Under the terms of the agreement, Arrowhead will conduct all activities through preclinical stages of development of the therapeutic. Horizon will receive a worldwide exclusive license to the therapeutic and will be wholly responsible for clinical development and commercialization. Arrowhead has received $175$40 million as an upfront payment. Separately, Johnson & Johnson Innovation — JJDC, Inc. (JJDC) made a $75 million equity investment in Arrowhead at a price of $23.00 per share of Arrowhead common stock. As discussed above, in April 2019, the Company earned a $25 million milestone payment from Janssen following the initiation of dosing in the triple combination cohort (cohort 12) in the Company’s ongoing Phase 1 / 2 study ofJNJ-3989(ARO-HBV)Horizon and an additional $25 million milestone payment from Janssen following the initiation of dosing in its phase 2b study ofJNJ-3989(ARO-HBV).
In addition, Arrowhead is eligible to receive up to approximately $1.6 billion$660 million in milestone payments under the license agreement. Arrowhead is also eligible to receive approximately $1.9 billion in optionpotential development, regulatory and milestone payments under the collaborationcommercial milestones, and option agreement related to up to three additional targets. Arrowhead is further eligible to receive tiered royalties upin the low- to mid teens under the license agreement and up to low teens under the collaboration and option agreementmid-teens range on net product sales.
In fiscal 2019, Janssen selected its first of potentially three RNAi therapeutics under our 2018 collaboration agreement,ARO-JNJ1, against an undisclosed target.
In 2019, wefiscal 2021, Arrowhead continued to develop and deploy our Targeted RNAi Molecule platform or (“TRiM™,) to identify and develop new therapeutics, includingARO-HIF2,ARO-HSD,ARO-DUX4. andARO-ENaC . TRiM™ utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting, while being structurally simple. The TRiM™ platform is designed to offer several potential competitive advantages including:
A more sophisticated RNAi trigger selection and screening process that identifies potent sequences rapidly in locations that RNAi competitors may miss;
Multiple routes of administration including subcutaneous, intravenous and inhaled;
Faster time to clinical candidates;
| 18 | |
2022 PROXY STATEMENT Executive Compensation
Optimal pharmacologic activity and longduration-of-effect;
Potentially wide safety margins;
Simplified manufacturing at reduced cost; and
And, theThe promise of taking RNAi to tissues beyond the liver.
We are focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics.
The timing of our planned and already filed clinical trial applications (CTA)(“CTA”) discussed below are based on calendar years, not fiscal years.
|
2020 PROXY STATEMENT Executive Compensation
Clinical Stage Candidates
ARO-AAT is a clinical-stage RNAi therapeutic candidate for the treatment of liver disease associated withalpha-1 antitrypsin deficiency.ARO-AAT is designed to knock down theAlpha-1 antitrypsin (AAT) gene transcript and reduce the hepatic production of the mutant AAT protein.ARO-AAT is a next-generation subcutaneously administered compound that follows a previous generation AAT compoundARC-AAT.
2017:ARO-AAT nominated; CTA filed
|
Three monthly doses of 300 mgARO-AAT led to reductions in serumalpha-1 antitrypsin to below the level of quantitation in 100% of subjects.
Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible.
Single and multiple doses ofARO-AAT appeared to be well-tolerated at all doses tested.
2019: One phase 2/3 and one Phase 2 trial were initiated (enrolling concurrently):
SEQUOIA, a potentially pivotal multi-center, multi-dose, placebo-controlled, adaptive Phase 2/3 study to evaluate the safety, efficacy and tolerability ofARO-AAT, administered subcutaneously to patients withalpha-1 antitrypsin deficiency
AROAAT2002, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response toARO-AAT over time in patients withalpha-1 antitrypsin deficiency associated liver disease.
ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3)(“ANGPTL3”), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease.
2017: Target identifiedidentified.
2018: Filed for regulatory clearance to begin a Phase 1 study.
2019: Clinical trial commenced. Initial results from AROANG1001 presented at the 2019 Global Summit on Cardiology and heartHeart Diseases and the November 2019 American Heart Association meeting. Key data include:
Dose dependent reductions in serum ANGPTL3 (mean maximum reduction ranging from 55% in the 35 mg cohort to 83% in the 300 mg cohort), which were maintained through the end of the study.
Dose dependent reduction in triglycerides andVLDL-C (mean maximum triglyceride reduction ranging from 31% in the 35 mg cohort and 66% in the 200 mg cohort and mean maximumVLDL-C ranging from 30% in the 35 mg cohort to 65% in the 200 mg cohort). Reductions in triglyceridestrig2lycerides andVLDL-C in the 200 mg and 300 mg cohorts were maintained through end of study.
2020: Completed planned enrollment in AROANG1001 and published additional preliminary data.
2021: Dosed the first patient in AROANG3-2001, a Phase 2b clinical study.
ARO-APOC3 is designed to reduce production of ApolipoproteinC-III(apoC-III)C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs)(“TRLs”) including VLDL and chylomicrons and a key regulator of triglyceride metabolism. The companyArrowhead believes that knocking down the hepatic production ofapoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs and better clearance of VLDL and chylomicron remnants.
2017: Target identifiedidentified.
2019: Clinical trial commenced. Initial results from AROAPOC31001 presented at the 2019 Global Summit on Cardiology and heartHeart Diseases and the November 2019 American Heart Association meeting. Key data include:
Dose dependent reductions in serum APOC3 (mean maximum reduction ranging from 72% in the 10 mg cohort to 94% in the 100 mg cohort), which were maintained through the end of the study.
Dose dependent reduction in triglycerides andVLDL-C (mean maximum triglyceride reduction ranging from 53% in the 10 mg cohort and 64% in the 100 mg cohort and mean maximumVLDL-C ranging from 53% in the 10 mg cohort to 68% in the 50 mg cohort). These reductions were maintained through the end of study.
2020: Completed planned enrollment in AROAPOC31001 and published additional preliminary data.
2021: Dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study in adults with severe hypertriglyceridemia, and the first patient in AROAPOC3-2002, a Phase 2b clinical study in adults with mixed dyslipidemia. Reported interim results demonstrating that (a) in patients with familial chylomicronemia syndrome (“FCS”) as compared to NON-FCS patients, safety parameters were similar and comparable and similar levels of APOC3 and changes in key lipid parameters were observed and (b) in patients with severe hypertriglyceridemia (“sHTG”), ARO-APOC3 was well tolerated, and consistently decreased APOC3, TG, and non-HDL-C, and increased HDL-C, independent of underlying genetic cause of HTG.
| 19 |
2022 PROXY STATEMENT Executive Compensation
ARO-ENaC is an orally inhaled investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
2020: Investigational New Drug application (“IND”) filed and Phase 1/2a clinical trial commenced.
2021: Voluntarily paused further dosing in our Phase 1/2 trial after receiving preliminary information from an ongoing chronic toxicology study in rats that contained unexpected signals of local lung inflammation.
ARO-HIF2 is being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC)(“ccRCC”). ccRCC is one of the most common forms of kidney cancer. Most patients with ccRCC have a mutation in the Von Hippel-Lindau gene, rendering them unable to degradeHIF-2a, which leads to accumulation during tumor hypoxia and promotes tumor growth.
2019: Investigational New Drug application (IND)IND filed.
|
2020 PROXY STATEMENT Executive Compensation2020: Commenced patient enrollment in a Phase 1 study.
2021: Reported interim results showing that HIF2 has been well-tolerated to-date and demonstrating (a) reductions in HIF2a in 7 of 9 patients who had tumor samples which could be evaluated and (b) some potentially early signs of efficacy in at least one patient.
ARO-HSDARO-C3 is being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases such as nonalcoholic steatohepatitis (NASH).ARO-HSD is designed to reduce the production of HSD17B13,complement component 3 as a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids, and bile acids. Published genetic data indicate a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis, and NASH. This genetic validation gives us confidence about the target gene.potential treatment for various complement mediated diseases.
2019: Clinical trial2021: Filed an application filed.for clearance to begin Phase 1/2a clinical trials.
Partnered Programs
ARO-AAT is a clinical-stage RNAi therapeutic candidate for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. ARO-AAT is designed to knock down the Alpha-1 antitrypsin (“AAT”) gene transcript and reduce the hepatic production of the mutant AAT protein. ARO-AAT is a next-generation subcutaneously administered compound that follows a previous generation AAT compound ARC-AAT.
2017: ARO-AAT nominated; CTA filed.
| • | 2018: Clinical trial commenced. Initial results from AROAAT1001 were presented in November 2018 at The Liver Meeting®, the Annual Meeting of the AASLD. Key data include: |
Three monthly doses of 300 mg ARO-AAT led to reductions in serum alpha-1 antitrypsin to below the level of quantitation in 100% of subjects.
Reductions were sustained for greater than 14 weeks indicating that quarterly or less frequent dosing appears feasible.
Single and multiple doses of ARO-AAT appeared to be well-tolerated at all doses tested.
2019: One phase 2/3 and one Phase 2 trial were initiated (enrolling concurrently):
SEQUOIA, a potentially pivotal multi-center, multi-dose, placebo-controlled, adaptive Phase 2/3 study to evaluate the safety, efficacy and tolerability of ARO-AAT, administered subcutaneously to patients with alpha-1 antitrypsin deficiency
AROAAT2002, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease.
2020: Presented new clinical data showing ARO-AAT strongly reduced the production of mutant Z-AAT protein and led to improvements in multiple biomarkers of alpha-1 liver disease; Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT earning a $300 million up-front payment and $740 million in potential milestone payments, as well as a 50/50 profit sharing agreement in the United States, and 20-25% royalties on sales outside of the United States.
2021: Granted Breakthrough Therapy Designation. Reported interim clinical data showing that ARO-AAT reduced the production of Z-AAT protein, reduced histological globule burden, improved liver fibrosis and improved biomarkers of liver health.
JNJ-3989 (formerlyARO-HBV) is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection with the goal of achieving a functional cure.JNJ-3989(ARO-HBV)JNJ-3989 (ARO-HBV) is a next-generation subcutaneously administered compound that follows previous generation HBV compoundsARC-520 andARC-521.
2017:JNJ-3989(ARO-HBV)JNJ-3989 (ARO-HBV) nominated; CTA filed.
| • | 2018: Clinical trial commenced. Clinical data presented at the World Gastroenterologists Summit and at the AASLD Liver Meeting® 2018 demonstrating: |
| 20 | |
2022 PROXY STATEMENT Executive Compensation
Mean HBsAg reduction of-1.9 Log10(-98.7%) with a range of-1.3 Log10(-95.0%) to-3.8 Log10(-99.98%).
JNJ-3989(ARO-HBV)JNJ-3989 (ARO-HBV) appeared to be well-tolerated at monthly doses up to 400 mg.
| • | 2018: Signed a license agreement with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceuticals Companies of Johnson & Johnson, for |
The total potential deal value is approximately $3.7 billion plus royalties on commercial sales.
Received $175 million as an upfront payment and received $75 million in the form of an equity investment by Johnson & Johnson Innovation — JJDC, Inc., at a premium price of $23.00 per share of Arrowhead common stock.
2019: Arrowhead initiated dosing in the triple combination cohort (cohort 12) in the Company’sits ongoing Phase 1 / 1/2 study ofJNJ-3989(ARO-HBV)JNJ-3989 (ARO-HBV) earning a $25 million milestone payment. The CompanyArrowhead earned an additional $25 million milestone payment following the initiation of dosing in itsJanssen’s phase 2b study ofJNJ-3989(ARO-HBV)JNJ-3989 (ARO-HBV).
2019:2021: Janssen selected onepresented clinical data from REEF-1, a Phase 2b study of its three potential targets underdifferent combination regimens, including JNJ-3989, and/or JNJ-56136379 (JNJ-6379), and a nucleos(t)ide analog (NA) for the 2018 collaboration agreementtreatment of chronic hepatitis B virus infection (CHB). The data showed that all regimens in the study were generally well tolerated and had a favorable safety profile, and a dose dependent response, with the Company is developing a drug,following results for the ARO-JNJ1,JNJ-3989 under200 mg (highest dose) arm at Week 48: (a) 19.1% of patients met the collaboration.primary endpoint (NA stopping criteria (ALT less than 3 times upper limit of normal, HBV DNA less than the lower limit of quantitation, HBeAg negative, and HBsAg less than 10 IU/mL)) and (b) 74.7% of patients achieving HBsAg <100 IU/mL.
Olpasiran (formerly AMG 890 (formerlyand ARO-LPA) is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels.
2016: Amgen, Inc. (“Amgen”) acquired a worldwide, exclusive license to develop and commercialize AMG 890(ARO-LPA).
2018: Amgen administersadministered the first dose of AMGolpasiran (AMG 890 / (ARO-LPA)ARO-LPA) in a Phase 1 clinical study, which earned Arrowhead a $10 million milestone payment.
2020: Amgen administered the first dose of olpasiran (AMG 890 / ARO-LPA) in a Phase 2 clinical study, which earned Arrowhead a $20 million milestone payment.
ARO-AMG1JNJ-75220795 wasis being developed against an undisclosed genetically-validated cardiovascular target underas a license and collaboration agreement with Amgen. We completed the Arrowhead Deliverable, as defined in our collaboration agreement with Amgen, during 2018. The option period expired on August 7, 2019, and Amgen advised the Company it did not intend to exercise its option.
potential treatment for nonalcoholic steatohepatitis Candidates in Development(“NASH
”). ARO-ENaCJNJ-75220795 is designed to reduce expression in the liver of patatin like phospholipase domain containing 3 (PNPLA3).
2018: Entered into a research collaboration and option agreement with Janssen, which resulted in collaboration on JNJ-75220795.
2019: Janssen selected one of its three potential targets under the 2018 collaboration agreement and Arrowhead is developing a drug, JNJ-75220795 (formerly referred to as ARO-JNJ1), under the collaboration.
2021: Janssen disclosed that it is collaborating with Arrowhead on JNJ-75220795 and dosed the first patients in a phase 1 clinical trial. Earned a $10 million option exercise fee from Janssen in connection with Janssen’s option to develop and commercialize JNJ-75220795, and a further $10 million milestone payment from Janssen after Janssen dosed the fifth patient in a Phase 1 clinical study of JNJ-75220795.
ARO-HSD is being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases such as NASH. ARO-HSD is designed to reduce the production of HSD17B13, a member of the epithelial sodium channel alpha subunit (aENaC)hydroxysteroid dehydrogenase family involved in the airwaysmetabolism of hormones, fatty acids and bile acids. Published genetic data indicate a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis and NASH. This genetic validation gives us confidence about the lung. In cystic fibrosistarget gene.
2019: Clinical trial application filed.
2020: Dosed first patients increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. A CTA is planned for the first half of 2020.in a Phase 1/2 clinical study.
Financial Results
| • |
|
|
|
20202022 PROXY STATEMENT Executive Compensation
ARO-XDH is being developed as a treatment for patients with uncontrolled gout. ARO-XDH is designed to reduce the production of xanthine dehydrogenase.
2021: Entered into global collaboration and license agreement with Horizon.
Candidates in Development
ARO-Lung2 is being developed against an undisclosed target as a potential treatment for chronic obstructive pulmonary disorder (COPD).
ARO-COVis being developed to address the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.
ARO-DUX4 is Arrowhead’s first muscle-targeted investigational RNAi therapeutic candidate, which is designed to target the gene that encodes human double homeobox 4 (“DUX4”) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy (“FSHD”). FSHD is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration.
2021: Presented pre-clinical data which suggests that ARO-DUX4 achieved good target engagement which led to a downstream beneficial physiological change, and which may support advancement into clinical studies.
Financial Results
| • | Revenue — Generated revenue of $138.3 million, compared to revenues of $88.0 million in fiscal 2020 and $168 million in fiscal 2019; |
| • | Net |
| • | Net Loss Per Share — Recorded net loss per share (diluted) of $1.36, compared to net loss per share (diluted) of $0.84 in fiscal 2020 and net income per share (diluted) of $0.69 in fiscal |
| • | Cash at end of fiscal |
| • | Total Stockholder Return — |
| 22 | |
2022 PROXY STATEMENT Executive Compensation
The comparisons in the above graph are based on historical data and are not intended to forecast the possible future performance of our common stock.
Executive Compensation Highlights
Aggressive Performance Fueled by Incentives
The Compensation Committee expects and has observed aggressive performance from the executive management team as evidenced by stellar stockholder return as compared against major indices and our peer group. Our philosophy has been to fuel this expectation with reasonably aggressive incentive compensation, and in particular to offer substantial incentive compensation to our CEO that is 100% at risk if we do not see aggressive corporate performance. For fiscal years 2021 and 2022, we have tightened the requirement such that the most substantial component of our CEO compensation, his equity award, is realized only if stockholders realize sustainable commensurate value in their holdings. Based on our overall operating environment and these results, the Compensation Committee took the following key actions and maintained key policies with respect to the compensation of our Named Executive OfficersNEOs for 2019:fiscal 2021:
| • | Base Salary — Approved base salary increases of |
| • | Annual Incentive Compensation — Approved annual cash bonuses for |
| • | Equity Compensation — Granted our CEO a long-term incentive compensation opportunity in the form of a performance-based restricted stock unit (“PRSU”) award. The original CEO PRSU award |
| • | Clawback Policy — Maintained a clawback policy allowing |
| 23 |
2022 PROXY STATEMENT Executive Compensation
| • | Ownership Guidelines — Maintained the achievement of stock ownership guidelines of six times his annual base salary for our CEO and twice |
| • | “Double Trigger” Feature for Acceleration of Equity Awards — Maintained the agreements for outstanding equity awards granted to our CEO pursuant to our 2004 Equity Incentive Plan and our 2013 and 2021 Incentive |
Advisory Vote to Approve Named Executive Officer Compensation
At our 20192021 Annual Meeting of Stockholders in March 2019,2021, we conducted anon-binding stockholder advisory vote to approve the compensation of our Named Executive OfficersNEOs (commonly known as a“Say-on-Pay” vote). Our stockholders approveddid not approve theSay-on-Pay proposal with approximately 97%a majority of the votes cast in favor of the proposal.votes. Based on the vote and feedback from our stockholders, we attributebelieve the high approval percentage primarilyprimary reason for the failure of the 2021 Say-On-Pay vote was a concern that the performance milestones associated with our CEO PRSU may not result in commensurate increase in stockholder value.
We believe that our incentive compensation package for our CEO should be an aggressive, performance-based award, and acknowledge the concerns of our stockholders that the link between the value of our current and future CEO PRSU awards could be more clearly linked to the following factors:stockholder return. Accordingly, we have taken steps to address these stockholder concerns:
ContinuedThe performance-based equity award granted to our CEO for 2021, as described in further detail below, consists of successive milestones that are solely based on an increase in market capitalization that are sustained over time. Thus, the grant is in direct alignment with the investment goals of our stockholders.
We have, in agreement with our CEO, reformulated the previous 2020 CEO PRSU award to require, in addition to the current vesting milestones, that the award vests only if at the time of certification of milestone performance our market capitalization has increased from the date the award was granted. This additional provision, or “trigger,” ensures the alignment between achievement of the performance goals under the award and an increase in stockholder value.
We have continued the practice of grantingawarding 100% performance-based equity awards for our CEO. No component of our CEO whichequity compensation structure results in the vesting of an award to our CEO without the achievement of performance goals tied directly to stockholder value creation.
The reformulation of our CEO equity compensation program is preferred by stockholders and unusual inentirely unique among our peer group;group in that it fully aligns the interests of our CEO and our stockholders. While our incentive compensation package for our CEO remains aggressive, the overwhelming majority of our CEO’s compensation is attained only if stockholders realize a commensurate benefit. No component of the equity compensation granted to our CEO is solely time-based, and every vesting opportunity requires the delivery of stockholder value.
Additionally, we:
Maintained our commitment to good corporate governance by continuing the following compensation practices:practices in our executive compensation program: minimum vesting requirements; a compensation recovery (“clawback”) policy, double-trigger acceleration of equity awards for our CEO; and stock ownership guidelines for our CEO CFO and COO;CFO;
Achievement ofAchieved aggressive corporate performance goals in 2018fiscal 2021 and 2019;fiscal 2020;
Continued to perform exceedingly well in comparison to relevant stock market indices; and
Substantial increases in market capitalization and TSR in 2018 and 2019.
In 2019, we continued our stockholder engagement program, reaching out to our top 20 institutional stockholders beneficially owning over 50%Delivered three-year Total Stockholder Return (“TSR”) that was at the 100th percentile of our outstanding common stock to solicit their views and concerns and reviewed the feedback and policies of ISS. Based on this review,peer group as well as our commitment to good corporate governance, as noted above, the Compensation Committee continued the above mentioned practices for the executive compensation reviewmeasured in 2019.November 2020.
DuringAt our 2019 annual meeting in March 2019,Annual Meeting of Stockholders, we asked our stockholders to recommend the frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers.our NEOs. Stockholders recommended an annualnon-binding vote, and we are following that recommendation.
|
2020 PROXY STATEMENT Executive Compensation
We value the opinions of our stockholders and will continue to consider the outcome of futureSay-on-Pay votes, as well as feedback received throughout the year, when making compensation decisions for our executive officers. The Compensation Committee is committed to being responsive to stockholder feedback regarding our executive compensation program, policies, and practices, including concerns expressed through theSay-on-Pay vote.
| 24 | |
2022 PROXY STATEMENT Executive Compensation
Pay-for-Performance Analysis
We believe our executive compensation program is reasonable, competitive and appropriately balances the goals of attracting, motivating, rewarding, and retaining our executive officers with the goal of aligning their interests with those of our stockholders. To ensure this alignment and to motivate and reward individual initiative and effort, a significant portion of our executive officers’ target annual total direct compensation opportunity is both performance-based and“at-risk.”
We emphasize performance-based compensation that appropriately rewards our executive officers, including our Named Executive Officers,NEOs, through two separate compensation elements:
First, we provide the opportunity to participate in our annual incentive compensation plan which provides cash payments if they produce short-term financial, operational, and strategic results that meet or exceed the objectives set forth each year in our annual operating plan.
In addition, we grant equity awards as long-term incentive compensation. For our CEO in fiscal 2019,2021, as described above, this award is to be earned based entirely on the achievement ofpre-established corporate market capitalization performance objectives whichthat are both challengingsubstantial and designed to drive our financial and operational performance and long-term growth, and, in the case of our other executive officers, are either dependent on the future appreciation in value of our common stock or are subject to the risk of fluctuations in the value of our common stock and, therefore, are “at risk.”
The pay mix for our CEO for each of the last three fiscal years illustrates the ongoing emphasis on our performance-based compensation philosophy:
We believe that, ultimately, the creation of sustainable long-term stockholder value will depend on our ability to successfully bring to market the products we develop or partner with strategic collaborators to bring them to market. Consequently, the Compensation Committee strives to incent our executive officers to create that value through the discovery and development of a robust and attractive pipeline of drug candidates. As a result,To achieve that end, our executive compensation program is designed to provide incentives that facilitate these efforts. Particularly for our CEO, the Compensation Committee has awarded performance milestone-based-based equity awards directly linked to goals that promote the development of our pipeline and other related business and market-based objectives. The Compensation Committee closely tracks the progress against these objectives to monitorand, in conjunction with our success over each product’s development period and evaluates our executive officers primarily on that progress.full Board of Directors, ensures the objectives are met using sound, ethical business practices before certifying performance achievement of the awards.
To ensure that we remain faithful to our compensation philosophy, the Compensation Committee regularly evaluates the relationship between the reported values of the equity awards granted to our executive officers, the amount of compensation realizable (and, ultimately, realized) from such awards in subsequent years and our total stockholder return over this period.
|
20202022 PROXY STATEMENT Executive Compensation
Executive Compensation Policies and Practices
We endeavor to maintain sound governance standards consistent with our executive compensation policies and practices. The Compensation Committee evaluates our executive compensation program on a regular basis to ensure that it is consistent with our short-term and long-term goals given the dynamic nature of our business and the market in which we compete for executive talent. The following summarizes our executive compensation and related policies and practices:
WHAT WE DO
|
WHAT WE DON’T DO
| |||||
✓ Maintain an Independent Compensation Committee. The Compensation Committee consists solely of independent directors.
✓ Retain an Independent Compensation Advisor. The Compensation Committee engaged its own compensation advisor to provide information and analysis with its
✓Annual Executive Compensation Review.
✓Compensation
✓CEO Equity Awards Require Increased Stockholder Value. The outstanding PRSU awards granted to our CEO were either issued to require, or have been revised to require, the demonstration of increased stockholder value before the awards are certified. ✓Stock Ownership Policy. We maintain a stock ownership policy that requires our CEO
✓Compensation Recovery (“Clawback”) Policy. We have established a clawback policy allowing
✓Conduct an Annual Stockholder Advisory Vote on
✓Use aPay-for-Performance Philosophy. The majority of our CEO’s compensation is directly linked to
✓“Double Trigger” Feature for Acceleration of CEO Equity Awards — The outstanding equity awards granted to our CEO pursuant to our |
| |||||
|
20202022 PROXY STATEMENT Executive Compensation
Executive Compensation Philosophy
Our executive compensation philosophy reflects our two fundamental objectives:
to attract, motivate and retain a highly skilled team of executives; and
to align our executive officers’ interests with those of our stockholders by rewarding short-term and long-term performance and aligning compensation to increases in stockholder value.
We believe that the compensation of our executive officers should be directly linked to the achievement of specific objectives that are expected to increase stockholder value. In furtherance of this goal, the Compensation Committee has established the following guidelines as a foundation for compensation decisions:
provide a competitive total compensation package that enables us to attract, retain and motivate highly-qualified executives with the skills and experience required for the achievement of business goals;
promote the achievement of key strategic and financial performance measures by linking short-term and long-term compensation to the achievement of measurable goals;
reward significant achievements outside ofpre-established goals;
recognize that pharmaceutical research, development and commercialization require sustained and focused effort over many years, and involve a high degree of risk and therefore balance incentives for short-term and long-term compensation;
employ outside compensation expertise and market data from industry peers to help assure that our compensation policies and practices are consistent with industry practice and meet our goals for our compensation program;
consider our cash resources and cost of capital to balance cash and equity compensation; and
align our executive officers’executives’ incentives with the creation of stockholder value.
Executive Compensation Program Design
Our practice is to combine a mixture of compensation elements that balance achievement of our short-term goals with our longer-term performance. Currently, our executive compensation program consists of three principal elements:
base salary;
an annual incentive compensation opportunity; and
long-term incentive compensation in the form of equity awards.
We believe that cash compensation in the form of base salary and an annual incentive compensation opportunity provides our executive officers with short-term rewards for success in operations, and that long-term incentive compensation in the form of RSU and PRSU awards that may be settled for shares of our common stock, and options to purchase shares of our common stock, align the objectives of our executive officers with those of our stockholders with respect to long-term performance and success. We have agreed with our CEO that certification of all outstanding CEO PRSU awards will only occur if our market capitalization has increased from the date of the award.
The Compensation Committee takes into consideration, among other things, our financial and working capital condition when approving performance objectives and making compensation decisions for our executive officers. Since we seek to preserveinvest our cash prudently and do not have marketed products, overall target total direct compensation opportunities are weighted more heavily toward long-term incentive compensation in the form of equity awards. Thus, a significant portion of each executive officer’s target total direct compensation is “at risk,” and dependent on the increase in the value of our common stock. The Compensation Committee periodically reassesses the appropriate weighting of cash and equity compensation.
In the case of long-term incentive compensation, typically the Compensation Committee designs these awards to vest, or be earned, over a multi-year period, meaning that long-term value creation, contrasted with short-term gain, presents the best opportunity for our executive officers to benefit from their awards.
We do not maintain a specific policy on the percentage allocation between short-term and long-term incentive compensation elements.
|
20202022 PROXY STATEMENT Executive Compensation
Governance of Executive Compensation Program
Role of the Compensation Committee
The Compensation Committee discharges many of the responsibilities of our Board of Directors relating to the compensation of our executive officers, including our Named Executive Officers,NEOs, and thenon-employee members of our Board.Board of Directors. The Compensation Committee has overall responsibility for overseeing our compensation and benefits philosophy and policies generally, overseeing and evaluating the compensation plans, policies and practices applicable to our CEO and our other executive officers, and ensuring that the target total direct compensation opportunities of our executive officers, including our Named Executive Officers,NEOs, are consistent with our compensation philosophy, policies and objectives.
The members of the Compensation Committee are appointed by our Board of Directors, and each member is an independent director (as “independence” is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). Currently, the members of the Compensation Committee are Michael S. Perry (Chairman)William Waddill (Committee Chair), Marianne De Backer, Mauro Ferrari, Adeoye Olukoton and William Waddill.Michael Perry.
The Compensation Committee reviews our executive compensation program annually on a calendar year basis, generally in December. The Compensation Committee draws on a number of resources to assist in the evaluation of the various components of our executive compensation program including, but not limited to, input from our CEO, the advice of an external compensation consultant (as identified below) retained by the Compensation Committee, information provided in the public filings of industry peers and industry data compiled yearly by Radford in its Global Life Sciences Survey, which represents a nationally-based assessment of executive compensation widely used within the pharmaceutical and biotechnology industry sectors.
The Compensation Committee relies upon the judgment of its members in making compensation decisions. In addition, the Compensation Committee incorporates judgment in the assessment process to respond to and adjust for the evolving business environment. The members of the Compensation Committee have extensive experience in executive management, as well as compensation practices and policies.
Compensation-Setting Process
The Compensation Committee develops recommendations for the target total direct compensation opportunities for our executive officers, including our Named Executive Officers.NEOs. The Compensation Committee does not use a single method or measure in making its compensation decisions, nor does it position compensation levels based upon a specific or target level relative to a peer group or other companies. Nonetheless, the pay practices at other companies are an important factor that the Compensation Committee considers in assessing the reasonableness of compensation and ensuring that our compensation practices are competitive in the marketplace.
Generally, the Compensation Committee evaluates the compensation of our executive officers relative to the median of the competitive market. However, as discussed hereafter, various other factors are taken into consideration in determining our executive officers’ compensation and the Compensation Committee does not target compensation at any specific level relative to the competitive market. When reviewing our current executive compensation arrangements and approving each compensation element and the target total direct compensation opportunity for our executive officers, the Compensation Committee considers the following factors:
Our performance against the financial and operational objectives established by the Compensation Committee and our Board;Board of Directors;
Each individual executive officer’s skills, experience and qualifications relative to other similarly-situated executives at the companies in our compensation peer group;group and in selected broad-based compensation surveys;
The scope of each executive officer’s role compared to other similarly-situated executives at the companies in our compensation peer group;group and in selected broad-based compensation surveys;
The performance of each individual executive officer, based on a subjective assessment of his or her contributions to our overall performance, ability to lead his or her business unit or function and work as part of a team, all of which reflect our core values;
The compensation practices of our compensation peer group and the companies in selected broad-based compensation surveys and the positioning of each executive officer’s compensation in a ranking of peer company compensation levels; and
The recommendations provided by our CEO with respect to the compensation of our other executive officers.
|
20202022 PROXY STATEMENT Executive Compensation
These factors provide the framework for compensation decision-making and final decisions regarding the compensation opportunity for each executive officer. No single factor is determinative in setting pay levels, nor was the impact of any factor on the determination of pay levels quantifiable.
Role of Chief Executive Officer
In discharging its responsibilities, the Compensation Committee works with members of our management, including our CEO. Our management assists the Compensation Committee by providing information on corporate and individual performance, market compensation data and management’s perspective on compensation matters. The Compensation Committee solicits and reviews our CEO’s recommendations with respect to the compensation levels for individual executive officers other than himself based on thehis performance evaluation of each executive officer’s manager and his own evaluation of the executive officer’s performance.officer.
The Compensation Committee reviews and discusses these recommendations and proposals with our CEO and considers them as one factor in formulating the recommendations fordetermining the compensation for our executive officers, including our other Named Executive Officers.NEOs. Our CEO recuses himself from all discussions and recommendations regarding his own compensation.
Role of Compensation Consultant
The Compensation Committee engages an external compensation consultant to assist it by providing information, analysis and other advice relating to our executive compensation program and the decisions resulting from its annual executive compensation review. The Compensation Committee has the final authority to engage and terminate the engagement of any compensation consultant that it retains.
For the period from October 2018 through the present, the Compensation Committee has engaged Compensia, Inc. (“Compensia”), a national compensation consulting firm, as its external compensation consultant.consultant (“Compensia”). Compensia assisted the Compensation Committee in its review of executive officer andnon-employee director compensation practices for 2019,fiscal 2021, including the competitiveness of compensation levels, executive compensation design, comparisons with our industry peers, and other technical considerations, such as:considerations. Such assistance included:
Review and update of our compensation peer group;
Review and analysis of the compensation arrangements for our executive officers, including our Named Executive Officers;NEOs;
Review and analysis of the compensation arrangements for thenon-employee members of our Board;Board of Directors;
Review and update of the Compensation Discussion and Analysis section of our proxy statement for our 20202022 Annual Meeting of Stockholders; and
| • | Support on otherad hoc matters. |
The terms of Compensia’s engagement include reporting directly to the Compensation Committee and to the Compensation Committee chair.Chair.
In 2019,2021, Compensia did not provide any other services to us. The Compensation Committee has evaluated Compensia’s independence pursuant to the listing standards of the Nasdaq and the relevant SEC rules and has determined that no conflict of interest has arisen as a result of the work performed by Compensia.
Competitive Positioning
For each of the past sixeight years, the Compensation Committee has directed its external compensation consultant to conduct a comparative study and report on compensation levels and practices relative to industry peers, including a competitive assessment of our executive compensation program as compared to the market data for base salaries, target total cash compensation, long-term incentive compensation and target total direct compensation. Typically, the findings of this study are presented to the Compensation Committee by the compensation consultant in conjunction with the Compensation Committee’s annual review of our executive compensation program.
|
2020 PROXY STATEMENT Executive Compensation
Because the biotechnology sector is dynamic, the comparator group used by the Compensation Committee to assess the competitive positioning of the compensation of our executive officers is updated annually to ensure that peer companies continue to meet the established criteria. For purposes of its review of our executive compensation program in fiscal 2019,2021, the Compensation Committee directed Compensia to update its compensation peer group reflecting the competitive market for executive talent based on the following criteria:
Publicly-held,pre-commercial U.S. biotechnology companies;
| 29 |
2022 PROXY STATEMENT Executive Compensation
Companies with market capitalizations between 0.5x0.33x to 2.0x3.0x our market capitalization at the time of the peer selection; and
Companies with between 50 to 500 employees.
The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies. Consideration was also given to the frequency or infrequency with which a company was identified as a peer with other peer companies. The increase in the Company’s market capitalization indicated significant redesign of the peer group for 2019.2021.
For 2019,2021, the compensation peer group consisted of the following companies:
| ACADIA Pharmaceuticals | ||
| Acceleron Pharma | FibroGen | |
| Allakos | Global Blood Therapeutics | |
| Arena Pharmaceuticals | Momenta Pharmaceuticals | |
| bluebird bio | Novavax | |
| BridgeBio Pharma | Reata Pharmaceuticals | |
| Blueprint Medicines | ||
| ChemoCentryx | ||
Allogene Therapeutics, Atara Biotherapeutics, Audentes Therapeutics, Cytokinetics, Dicerna Pharmaceuticals, Iovance Biotherapeutics, Mirata Therapeutics, MyoKardia, Sangamo Therapeutics, Tricida, Voyager Therapeutics, Xencor and Zogenix were eliminated from the peer group and ACADIA Pharmaceuticals, Alnylam Pharmaceuticals, bluebird bio, BridgeBio Pharma, ChemoCentryx, CRISPR Therapeutics AG, FibroGen, Ionis Pharmaceuticals, Momenta Pharmaceuticals, Novavax, Reata Pharmaceuticals, Sarepta Therapeutics, Twist Bioscience and Ultragenyx Pharmaceuticals were added to the peer group due to changes in our business complexity, employee base and market capitalization, as well as mergers, changes to business complexity, employee base and market capitalization among our prior peer group.
The compensation study prepared by Compensia and presented in December 20192020 provided an assessment of our compensation practices as compared to industry peers. Compensation levels for our executive officers, in the aggregate, were determined to be within the range of compensation provided to similarly placed executives and consistent with our compensation philosophy.
Individual Compensation Elements
In 2019,2021, the principal elements of our executive compensation program were as follows:
base salary;
an annual incentive compensation opportunity;
long-term incentive compensation in the form of equity awards;
welfare and health benefits; and
post-employment compensation arrangements.
Base Salary
Base salary represents the fixed portion of the compensation of our executive officers, including our Named Executive Officers,NEOs, and is an important element of compensation intended to attract and retain highly-talented individuals.
The initial base salaries for our executive officers were negotiated on an individual basis at the time of hire. Thereafter, using the competitive market data provided by its compensation consultant, the Compensation Committee reviews and determines adjustments to the base salaries for each of our executive officers, including our Named Executive Officers,NEOs, as part of its annual executive compensation review. In addition, the base salaries of our executive officers may be adjusted by the Compensation Committee in the event of a promotion or significant change in responsibilities. Generally, the Compensation Committee sets base salaries with reference to the competitive range of the market median of our compensation peer group and applicable executive compensation survey data, as well as its assessment of the factors described in “Governance of Executive Compensation Program — Compensation-Setting Process” above.
|
20202022 PROXY STATEMENT Executive Compensation
The base salaries of our Named Executive OfficersNEOs for 2018fiscal 2020 and 2019fiscal 2021 were as follows:
Named Executive Officer
| 2019
| 2018
| Percentage Adjustment
| Fiscal 2021
| Fiscal 2020
| Percentage Adjustment
| ||||||||||||||||||||||||
Christopher Anzalone President & CEO
| $
| 682,500
|
| $
| 650,000
|
|
| 5
| %
| $ | 844,600 | $ | 820,000 | 3 | % | |||||||||||||||
Bruce Given Chief Operating Officer
| $
| 500,000
|
| $
| 455,000
|
|
| 10
| %
| |||||||||||||||||||||
Kenneth Myszkowski Chief Financial Officer
| $
| 430,000
|
| $
| 400,000
|
|
| 8
| %
| $ | 489,250 | $ | 475,000 | 3 | % | |||||||||||||||
Patrick O’Brien General Counsel
| $
| 426,400
|
| $
| 410,000
|
|
| 4
| %
| |||||||||||||||||||||
Zhen Li (1) Senior Vice President Chemistry &Non-Clinical Development
| $
| 390,000
|
| $
| 300,000
|
|
| 30
| %
| |||||||||||||||||||||
Patrick O’Brien General Counsel, Corp. Secretary, and Chief Compliance Officer | $ | 484,100 | $ | 470,000 | 3 | % | ||||||||||||||||||||||||
Javier San Martin Chief Medical Officer | $ | 463,500 | $ | 450,000 | 3 | % | ||||||||||||||||||||||||
James Hamilton Senior VP, Discovery and Translational Medicine | $ | 432,600 | $ | 420,000 | 3 | % | ||||||||||||||||||||||||
James Hassard (1) Former Chief Commercial Officer | $ | 437,750 | $ | 425,000 | 3 | % | ||||||||||||||||||||||||
| (1) |
|
The actual base salaries paid to our Named Executive OfficersNEOs in fiscal 20192021 are set forth in the “Fiscal 20192021 Summary Compensation Table” below.
Annual Incentive Compensation
We provide our executive officers, including our Named Executive Officers,NEOs, with the opportunity to earn performance-based annual incentive awards, payable in cash, which are designed to reward them for our overall corporate performance as well as their individual performance. Generally, our executive officers are evaluated each year for eligibility to receive an annual incentive compensation opportunity. Through a collaborative planning process involving our Board of Directors and management, corporate performance objectives are established at the beginning of each year and evaluated regularly by our Board of Directors for their continued relevance to our status.
Target Annual Cash BonusIncentive Award Opportunities
For purposes of the 2019fiscal 2021 performance-based incentive awards, each of our Named Executive OfficersNEOs was assigned a target annual incentive award opportunity based upon a percentage of his or her base salary. The target annual incentive award opportunities for our executive officers, including our Named Executive Officers,NEOs, were recommended by our CEO (except with respect to his own target annual incentive award opportunity) based on each executive officer’s accountability, scope of responsibilities, and potential impact on our performance, and approved by the Compensation Committee. The determination of target annual incentive award opportunities was based on the factors described in “Governance of Executive Compensation Program — Compensation-Setting Process” above. Based on higher levels of control and accountability for our overall performance, a higher percentage of each executive officer’s total target cash compensation was dependent on his or her performance-basedTarget annual incentive awards.award opportunities did not change in fiscal 2021.
The target annual incentive award opportunities for our Named Executive OfficersNEOs were as follows:
Named Executive Officer
| 2019 Target Annual
| 2018 Target Annual
| Fiscal 2021 Target Annual
| Fiscal 2020 Target Annual
| ||||||||||||||||
Dr. Anzalone
|
| 100
| %
|
| 100
| %
| 100 | % | 100 | % | ||||||||||
Dr. Given
|
| 70
| %
|
| 70
| %
| ||||||||||||||
Mr. Myszkowski
|
| 45
| %
|
| 45
| %
| 45 | % | 45 | % | ||||||||||
Mr. O’Brien
|
| 45
| %
|
| 45
| %
| 45 | % | 45 | % | ||||||||||
Dr. Li (1)
|
| 40
| %
|
| 40
| %
| ||||||||||||||
Dr. San Martin | 40 | % | 40 | % | ||||||||||||||||
Dr. Hamilton | 45 | % | 45 | % | ||||||||||||||||
Mr. Hassard (1) | 40 | % | 40 | % | ||||||||||||||||
| (1) |
|
|
20202022 PROXY STATEMENT Executive Compensation
Performance Objectives
In determining the amount of the annual incentive award for each of our executive officers, including each of our Named Executive Officers,NEOs, the Compensation Committee evaluated the corporate performance objectives that had been established at the beginning of the calendar year (as set forth below) as well as other corporate and individual achievements and performance throughout the year. These performance objectives addressed milestones for our lead products, research and development milestones for our drug pipeline and business development objectives. In December 2019,2021, the Compensation Committee determined that we had largely achieved or exceeded our primary business objectives set for calendar 2019,2021, as described below.
Goal
|
Achievement Highlights
| |
Corporate
Meet certain goals related to capital formation, market capitalization; board interface with scientific leaders |
Met,
Ended
cash | |
New Business DevelopmentWeight:
Meet certain goals with regard to new pharma collaborations |
Met
| |
Manufacturing Weight: 10%
Meet certain requirements pursuant to
|
Met, including stretch goals
Manufactured significant percentage of needs in-house | |
Meet certain goals with regard to progress on our pre-clinical and early clinical programs |
| |
|
Met, | |
Clinical DevelopmentWeight: 25% Meet certain goals relating to Phase 2 and 3 studies in our clinical programs. | Met, including some stretch goals
Complete ARO-AAT Phase 1/2 trial Complete enrollment of ARO-Hif2 Phase 1/2 trial Significant number of patients dose in two cardiometabolic trials.
| |
Meet certain goals for |
Met
|
|
20202022 PROXY STATEMENT Executive Compensation
Annual Incentive Award Payments
The actual annual incentive award payments earned by our Named Executive Officers ranged from 130% to 243%incumbent NEOs was 100% or more of their target annual incentive award opportunities. Except for the award for our CEO, these awards were recommended by our CEO and approved by the Compensation Committee based on the overall achievement of the Company’sour goals, their contributions to the goals and the overall performance of each executive officer during the year. The following table sets forth the target annual incentive award opportunities, the actual award payment as a percentage of each Named Executive Officer’sNEO’s base salary and the actual award payment made in cash to each of our Named Executive OfficersNEOs based on their performance in 2019:fiscal 2021:
Named Executive Officer
|
Target Annual
| Actual Annual
| Actual Annual Incentive Award
|
Target Annual
| Actual Annual
| Actual Annual Incentive Award
| ||||||||||||||||||||||||
Dr. Anzalone
|
| 100
| %
|
| 226
| %
| $
| 1,540,000
|
| 100 | % | 100 | % | $ | 845,000 | |||||||||||||||
Dr. Given
|
| 70
| %
|
| 170
| %
| $
| 850,000
|
| |||||||||||||||||||||
Mr. Myszkowski
|
| 45
| %
|
| 59
| %
| $
| 251,550
|
| 45 | % | 47 | % | $ | 231,171 | |||||||||||||||
Mr. O’Brien
|
| 45
| %
|
| 59
| %
| $
| 249,444
|
| 45 | % | 50 | % | $ | 239,630 | |||||||||||||||
Dr. Li (1)
|
| 40
| %
|
| 0
| %
| $
| 0
|
| |||||||||||||||||||||
Dr. San Martin | 40 | % | 40 | % | $ | 185,400 | ||||||||||||||||||||||||
Dr. Hamilton | 45 | % | 54 | % | $ | 233,604 | ||||||||||||||||||||||||
Mr. Hassard (1) | 40 | % | — | % | $ | — | ||||||||||||||||||||||||
| (1) |
|
The annual incentive award payments made to our Named Executive OfficersNEOs for fiscal 20192021 are set forth in the “Fiscal 20192021 Summary Compensation Table” below.
Long-Term Incentive Compensation
We view long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. The realizable value of these equity awards over time bears a direct relationship to our stock price, and, therefore, these awards are an incentive for our executive officers, including our Named Executive Officers,NEOs, to create value for our stockholders. Equity awards also help us retain qualified executive officers in a competitive market.
Long-term incentive compensation opportunities in the form of equity awards are granted to our executive officers by the Compensation Committee. The amount and forms of such equity awards are determined by the Compensation Committee after considering the factors described in “Governance of Executive Compensation Program — Compensation-Setting Process” above.
20192021 Long-Term Incentive Awards
Performance-Based RSU Award for Chief Executive Officer
Annual equity awards granted to our executive officers are solely in the form of RSUrestricted stock unit (“RSU”) awards that may be settled for shares of our common stock. In the case of our CEO, the award is entirely performance-based. On January 1, 2019,2021, Dr. Anzalone was granted a performance-based RSU (“PRSU”) award of 600,000800,000 shares of our common stock to be vestedearned in three equal installments on the achievement of the following milestones:
Achieve a $9 billion market capitalization of $2 billion and hold for 6 six months;two fiscal quarters (250,000 shares)
FileAchieve a clinical trial application or IND$10 billion market capitalization and hold for lung- or muscle-targeted candidate; andtwo fiscal quarters (270,000 shares)
|
Achieve an $11 billion market capitalization and hold for two fiscal quarters (280,000 shares)
The milestones must be achieved by January 1, 20212025 or the grantportion of the PRSU tied to each specific milestone will expire.
|
20202022 PROXY STATEMENT Executive Compensation
Results from PRSU Awards Previously Granted
TheIn fiscal 2021, the Compensation Committee has certified achievement of the performance milestones and the vesting of the following PRSUs granted to our CEO.PRSU awards:
Performance Goal | Achievement
| No. of Shares Certified as Vested
| ||
Granted 01/01/2019
|
Certified |
200,000 shares pursuant to a PRSU award | ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
|
|
|
EquityRSU Awards for Other Named Executive Officers
The Compensation Committee approved the following aggregate equityRSU awards for our Named Executive OfficersNEOs for 2019:2021:
Named Executive Officer
| Restricted Stock Unit
| Restricted Stock Unit Grant Date Fair Values
| Restricted Stock Unit
| Restricted Stock Unit Awards
| ||||||||||||||||
Mr. Given
|
| 210,000
|
| $
| 2,608,200
|
| ||||||||||||||
Mr. Myszkowski
|
| 85,000
|
| $
| 1,055,700
|
| 60,000 | $ | 4,603,800 | |||||||||||
Mr. O’Brien
|
| 70,000
|
| $
| 869,400
|
| 60,000 | $ | 4,603,800 | |||||||||||
Dr. Li (1)
|
| 75,000
|
| $
| 931,500
|
| ||||||||||||||
Dr. San Martin (1) | N/A | N/A | ||||||||||||||||||
Dr. Hamilton | 50,000 | $ | 3,836,500 | |||||||||||||||||
Mr. Hassard (1) | N/A | N/A | ||||||||||||||||||
| (1) | Dr. |
|
2020 PROXY STATEMENT Executive Compensation
The awards vest over 4four years in 4four equal installments.
The equity awards granted to our Named Executive OfficersNEOs in fiscal 20192021 are set forth in the “Fiscal 20192021 Summary Compensation Table” and the “Fiscal 20192021 Grants of Plan-Based Awards Table” below.
Welfare and Health Benefits
Our executive officers, including our Named Executive Officers,NEOs, are eligible to participate in all of our employee benefit plans, including medical, dental, vision, life and disability insurance, in each case on the same basis as our other employees, subject to applicable law. In addition, we provide additional life insurance for our CEO for the benefit of his heirs. We also provide vacation and other paid holidays to all our employees, including our executive officers, all of which we believe to be comparable to those provided at peer companies. These benefit programs are designed to enable us to attract and retain our workforce in a competitive marketplace. Our health, welfare and vacation benefits are designed to ensure that we have a productive and focused workforce through reliable and competitive health and other benefits.
Our retirement savings plan (“401(k) plan”plan”) is atax-qualified retirement savings plan, pursuant to which qualified employees, including our Named Executive Officers,NEOs, are able to contribute certain amounts of their annual compensation, subject to limits prescribed by the Internal Revenue Service. Historically, we have made matching contributions of 100% of the first 3% of base salary and of 50% of the next 2% of base salary contributed to the plan. The value of these benefits for each of our Named Executive OfficersNEOs is reflected in the “All Other Compensation” column of the “Summary“Fiscal 2021 Summary Compensation Table” below.
Perquisites and Other Personal Benefits
Currently, we do not view perquisites or other personal benefits as a significant component of our executive compensation program. Accordingly, we do not provide significant perquisites or other personal benefits to our executive officers, including our Named Executive Officers,NEOs, except as generally made available to our employees, or in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective and for recruitment and retention purposes.
In the future, we may provide perquisites or other personal benefits in limited circumstances, such as those described in the preceding paragraph. All future practices with respect to perquisites or other personal benefits will be approved and subject to periodic review by the Compensation Committee.
| 34 | |
2022 PROXY STATEMENT Executive Compensation
We have entered into a written employment agreement with our CEO and have written employment offer letters with our other executive officers.In filling each of our executive positions, we recognized the need to develop competitive compensation packages to attract qualified candidates in a dynamic labor market. At the same time, in formulating these compensation packages, we were sensitive to the need to integrate new executive officers into the executive compensation structure that we were seeking to develop, balancing both competitive and internal equity considerations. Each of these arrangements provides for “at will” employment.
For detailed descriptions of the employment arrangements we maintained with our Named Executive Officers for 2019,NEOs during fiscal 2021, see “Termination Benefits — Potential Payments Upon Termination or Change in Control” below.
Post-Employment Compensation Arrangements
We have entered into ana written employment agreement with our CEO, and we also have agreements with our CFO and General Counsel that provide for certain payments and benefits in the event of certain involuntary terminations of employment. We believe that having in place reasonable and competitive post-employment compensation arrangements are essential to attracting and retaining highly-qualified executive officers. These agreements are designed to provide reasonable compensation to executive officers who leave our employ under certain circumstances to facilitate their transition to new employment. Further, in some instances we seek to mitigate any potential employer liability and avoid future disputes or litigation by requiring a departing executive officer to sign a separation and release agreement acceptable to us as a condition to receiving post-employment compensation payments or benefits.
The Compensation Committee does not consider the specific amounts payable under these agreements when establishing annual compensation. We do believe, however, that these arrangements are necessary to offer compensation packages that are competitive.
|
2020 PROXY STATEMENT Executive Compensation
In addition, our 2013 Incentive Plan and our 2021 Incentive Plan each provides for the acceleration of vesting of outstanding and unvested equity awards in the event of a change in control of the Company, as defined in the plan,plans, except as otherwise determined by our Board. The Company has amendedBoard of Directors. However, the agreements for outstanding equity awards granted to our CEO pursuant to our 2004 Equity2013 Incentive Plan and 2013our 2021 Incentive Plan to provide that, upon a change in control of the Company, the vesting of such awards will accelerate only in the event of a subsequent involuntary termination of employment (a “double-trigger” arrangement).
For detailed descriptions of the post-employment compensation arrangements we maintained with our Named Executive Officers for 2019,NEOs during fiscal 2021, as well as an estimate of the potential payments and benefits payable under these arrangements, see “Termination Benefits — Potential Payments Upon Termination or Change in Control” below.
Other Compensation Policies and Practices
Equity Awards Grant Policy
We do not have any program, plan, or obligation that requires us to grant equity awards on specified dates, although historically we have granted such awards to our existing executive officers and employees at least annually and to newly-hired employees on the commencement of their employment. We do not have any program, plan or practice to grant options to purchase sharesequity awards of our common stock to our executive officers in coordination with the release of material nonpublic information. Equity awards may occasionally be granted following a significant change in job responsibilities or to meet other special retention or performance objectives.
Authority to grant equity awards to our employees rests with the Compensation Committee, although the Compensation Committee has delegated authority to our CEO to grant equity awards tonon-executive employees within prescribed limits set by the Compensation Committee. With respect to our executive officers, except for our CEO, recommendations for equity awards are made by our CEO and reviewed and approved by the Compensation Committee.
Under the terms of our 20132021 Incentive Plan, pursuant to which new equity awards are granted, the exercise price of any option to purchase shares of our common stock awarded under the plan must be equal to at least 100% of the fair market value of our common stock (which is determined based on the closing sales price of our common stock on the Nasdaq Global Market) on the date of grant.
Stock Ownership Policy
We maintain a stock ownership policy for our CEO COO, and CFO to further align their respective interests with the interests of our stockholders, and to further promote our commitment to sound corporate governance. This policy requires our CEO to own a
| 35 |
2022 PROXY STATEMENT Executive Compensation
minimum number of shares of our common stock equal to a value of six times his annualized base salary and our COO and CFO to own a minimum number of shares of our common stock equal to a value of twice theirhis annualized base salary. Each of these executive officers has achieved the required ownership.
Compensation Recovery (“Clawback”) Policy
In December 2017, our Board of Directors adopted a compensation recovery (“clawback”) policy as follows:
“If Arrowhead Pharmaceuticals, Inc. (the “Company”) is required to materially restate any of its financial statements, the Board of Directors (the “Board”) shall assess the degree to which any fraud, negligence, or intentional misconduct by any executive officer of the Company was responsible for such restatement. If the Board determines that any executive officer was responsible for causing such restatement, the Board shall, in addition to any other lawful remedies the Board or the Company may take, seek recovery of all or a portion of the incentive compensation awarded to the executive officer for the performance period covered by the restated financial statement, provided that such recovery shall not extend to payments made more than three years prior to the date the financial record was restated. In addition, the Board may, in its absolute discretion, revoke any of the responsible executive officer’s unpaid or unvested incentive compensation outstanding as of the date of the Board’s determination of the executive officer’s responsibility for the financial restatement.”
In addition, our 2013 Incentive Plan and our 2021 Incentive Plan each provides for the recovery of awards made under the plan in accordance with any applicable compensation recovery or recoupment policy, including as required by law, regulation or national securities exchange rule.
|
2020 PROXY STATEMENT Executive Compensation
Policy Prohibiting Hedging and Limiting Pledging
Our Insider Trading Policy prohibits our employees, including our executive officers, and thenon-employee members of our Board of Directors from short-term trading, options trading, trading on margin, pledging our common stock as collateral, and all hedging transactions with respect to our securities, except for pledgingour board members and executive officers may pledge up to 50% owned and vested stock as collateral for a loan subject to the approval of the Board.our Board of Directors.
Tax and Accounting Considerations
Deductibility of Executive Compensation
Prior to the US Tax Cuts and Jobs Act enacted in December of 2017 (the “US Tax Act”), compensation that satisfied conditions set forth under Section 162(m) of the Internal Revenue Code to qualify as “performance-based compensation” was not subject to a $1 million limit on deductibility, and the limit did not apply to compensation paid to the Chief Financial Officer. The US Tax Act eliminates the performance-based compensation exception and applies the limit to the Chief Financial Officer and certain former executive officers. However, it provides a transition rule with respect to remuneration provided under a written contract which was in effect on November 2, 2017 and which was not materially modified after that date. With eliminatingelimination of the exemption for performance-based compensation, we expect that we will be unable to deduct all compensation in excess of $1 million paid to our Chief Executive Officer, Chief Financial Officer and our other Named Executive OfficersNEOs covered by the new tax law, other than previously granted awards that comply with the transition rules. We monitor the application of Section 162(m) and the associated Treasury regulations on an ongoing basis and the advisability of qualifying executive compensation for deductibility. Notwithstanding the repeal of the exemption for “performance-based compensation,” the Compensation Committee intends to maintain its commitment to structuring the Company’sour executive compensation programsprogram in a manner designed to align pay with performance.
Accounting for Stock-Based Compensation
We follow the Financial Accounting Standard Board’s Accounting Standards Codification Topic 718 (“FASB ASC Topic 718”718”) for our stock-based compensation awards. FASB ASC Topic 718 requires us to measure the compensation expense for all share-based payment awards made to our employees andnon-employee members of our Board of Directors, including options to purchase shares of our common stock and other stock awards, based on the grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may never realize any value from their awards.
| 36 | |
20202022 PROXY STATEMENT Executive Compensation
In reviewing our various compensation programs, the Compensation Committee considers how our compensation policies and practices may affect our risk profile and whether such policies and practices may encourage undue risk-taking by our employees. More specifically, the Compensation Committee considers the general design philosophy of our policies and practices for our employees whose conduct would be most affected by incentives established pursuant to these compensation policies. In considering these issues, the Compensation Committee concluded that the use of a performance-based annual incentive compensation plan and long-term incentive compensation opportunities in the form of equity awards did not appear to create undue risks for us or encourage excessive risk-taking behavior on the part of our Named Executive Officers.NEOs.
With respect to the annual incentive awards for our executive officers, the amount of an individual’s award depends principally on overall Company performance, as determined by the Compensation Committee, which reduces the ability and incentive for an individual to take undue risks at the expense of our performance in an effort to increase the amount of his or her annual incentive award. Our performance objectives are reviewed regularly by the Compensation Committee and our Board of Directors and are considered to be generally of the nature that promote the steady progression of our development programs and would not encourage or reward excessive risk-taking. In addition, our Board of Directors has the ability to intervene in instances where actions by our executive officersvis-à-vis Company performance objective attainment would be considered unduly risky to prevent or penalize such actions.
Compensation Committee Report
The Compensation Committee of the Company has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) ofRegulation S-K. Based on this review and discussion, the Compensation Committee recommended to theour Board of Directors that the foregoing Compensation Discussion and Analysis be included in this proxy statement.
Submitted by the Compensation
Committee of the Board of Directors
Michael S. Perry, ChairmanWilliam Waddill, Committee Chair
Marianne De Backer
Mauro Ferrari
William WaddillAdeoye Olukotun
Michael Perry
| 37 |
20202022 PROXY STATEMENT Executive Compensation
Compensation Committee Interlocks and Insider Participation
During 2019,2021, Dr. Perry, Dr. De Backer, Dr. Ferrari, Dr. Olukoton and Mr. Waddill served on the Compensation Committee. During fiscal year 20192021 and through December 2019,2021, there were no compensation committee interlocks between the Company and other entities involving the Company’s executive officers and directors.
Fiscal 2021 Summary Compensation Table
The following table summarizes compensation earned for services rendered during fiscal 2019, 2018,2021, 2020, and 20172019 by our Chief Executive Officer, our Chief Financial Officer, our Chief OperatingGeneral Counsel, Corporate Secretary and Compliance Officer, our General Counsel andChief Medical Officer, our Senior Vice President of ChemistryDiscovery andNon-Clinical Development, Translational Medicine, and our former Chief Commercial Officer, collectively our “Named Executive Officers”:
| Name and Principal Position | Year | Salary ($) | Stock ($) | Non-Equity ($) | All Other ($) | Total | Year | Salary ($) | Bonus (S) | Stock ($) | Non-Equity ($) | All Other ($) | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone
President and Chief Executive Officer
|
| 2019
|
|
| 674,375
|
|
| —
| (4)
|
| 1,540,000
|
|
| 1,889
|
|
| 2,216,264
|
|
|
2021
|
|
|
837,031
|
|
|
—
|
|
|
23,019,000
|
(4)
|
|
845,000
|
|
|
2,824
|
|
|
24,703,855
|
| ||||||||||||||||||||||||||
|
| 2018
|
|
| 643,012
|
|
| —
| (5)
|
| 975,000
|
|
| 1,889
|
|
| 1,619,901
|
|
| 2020
|
|
| 785,625
|
|
| —
|
|
| 12,686,000
| (5)
|
| 820,000
|
|
| 2,892
|
|
| 14,294,517
|
| |||||||||||||||||||||||||||
|
| 2017
|
|
| 616,068
|
|
| 537,900
| (6)
|
| 715,357
|
|
| 1,889
|
|
| 1,871,214
|
|
| 2019
|
|
| 674,375
|
|
| —
|
|
| —
| (6)
|
| 1,540,000
|
|
| 1,889
|
|
| 2,216,264
|
| |||||||||||||||||||||||||||
Kenneth Myszkowski Chief Financial Officer
|
| 2019
|
|
| 422,500
|
|
| 1,055,700
|
|
| 251,550
|
|
| 11,799
|
|
| 1,741,549
|
|
|
2021
|
|
|
484,865
|
|
|
—
|
|
|
4,603,800
|
|
|
231,171
|
|
|
13,734
|
|
|
5,333,570
|
| ||||||||||||||||||||||||||
|
| 2018
|
|
| 384,841
|
|
| 276,000
|
|
| 180,000
|
|
| 12,177
|
|
| 853,018
|
|
| 2020
|
|
| 463,750
|
|
| —
|
|
| 5,391,550
|
|
| 213,750
|
|
| 12,802
|
|
| 6,081,852
|
| |||||||||||||||||||||||||||
|
| 2017
|
|
| 336,099
|
|
| 224,750
|
|
| 152,713
|
|
| 11,809
|
|
| 725,371
|
|
| 2019
|
|
| 422,500
|
|
| —
|
|
| 1,055,700
|
|
| 251,550
|
|
| 11,799
|
|
| 1,741,549
|
| |||||||||||||||||||||||||||
Bruce D. Given
Chief Operating Officer
|
| 2019
|
|
| 488,750
|
|
| 2,608,200
|
|
| 850,000
|
|
| 11,799
|
|
| 3,958,759
|
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| 2018
|
|
| 450,362
|
|
| 644,000
|
|
| 445,900
|
|
| 11,799
|
|
| 1,552,061
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
|
| 2017
|
|
| 432,250
|
|
| 589,000
|
|
| 351,340
|
|
| 11,599
|
|
| 1,384,189
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Patrick O’Brien
General Counsel
|
| 2019
|
|
| 422,300
|
|
| 869,400
|
|
| 249,444
|
|
| 11,799
|
|
| 1,552,943
|
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| 2018
|
|
| 406,196
|
|
| 220,800
|
|
| 184,500
|
|
| 11,799
|
|
| 823,295
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
|
| 2017
|
|
| 390,988
|
|
| 224,750
|
|
| 177,653
|
|
| 11,599
|
|
| 804,990
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Zhen Li (7) Senior Vice President, Chemistry and Non- |
| 2019
|
|
| 150,257
|
|
| 931,500
|
|
| —
|
|
| 4,236
|
|
| 1,085,993
|
| |||||||||||||||||||||||||||||||||||||||||||||||
|
| 2018
|
|
| 287,462
|
|
| 239,200
|
|
| 150,000
|
|
| 9,462
|
|
| 686,124
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
|
| 2017
|
|
| 247,448
|
|
| 131,750
|
|
| 120,000
|
|
| 6,798
|
|
| 505,996
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Patrick O’Brien
General Counsel, Corp. Sect. and Chief Compliance Officer
|
|
2021
|
|
|
479,762
|
|
|
—
|
|
|
4,603,800
|
|
|
239,630
|
|
|
13,734
|
|
|
5,336,926
|
| ||||||||||||||||||||||||||||||||||||||||||||
|
| 2020
|
|
| 459,100
|
|
| —
|
|
| 4,440,100
|
|
| 211,500
|
|
| 12,802
|
|
| 5,123,502
|
| |||||||||||||||||||||||||||||||||||||||||||||
|
| 2019
|
|
| 422,300
|
|
| —
|
|
| 869,400
|
|
| 249,444
|
|
| 11,799
|
|
| 1,552,943
|
| |||||||||||||||||||||||||||||||||||||||||||||
Javier San Martin (7)
Chief Medical Officer
|
|
2021
|
|
|
459,346
|
|
|
—
|
|
|
—
|
|
|
185,400
|
|
|
13,734
|
|
|
658,480
|
| ||||||||||||||||||||||||||||||||||||||||||||
|
| 2020
|
|
| 380,769
|
|
| 100,000
|
|
| 7,225,500
|
|
| 180,000
|
|
| 12,802
|
|
| 7,899,071
|
| |||||||||||||||||||||||||||||||||||||||||||||
|
| 2019
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
|
| —
| �� | |||||||||||||||||||||||||||||||||||||||||||||
James Hamilton
Sr. VP Discovery and Translational Medicine |
|
2021
|
|
|
426,109
|
|
|
—
|
|
|
3,836,500
|
|
|
233,604
|
|
|
13,734
|
|
|
4,509,947
|
| ||||||||||||||||||||||||||||||||||||||||||||
|
| 2020
|
|
| 376,362
|
|
| —
|
|
| 2,854,350
|
|
| 169,363
|
|
| 12,802
|
|
| 3,412,877
|
| |||||||||||||||||||||||||||||||||||||||||||||
|
| 2019
|
|
| 351,831
|
|
| —
|
|
| 745,200
|
|
| 109,620
|
|
| 11,505
|
|
| 1,218,156
|
| |||||||||||||||||||||||||||||||||||||||||||||
James Hassard (8)
Chief Commercial Officer |
|
2021
|
|
|
431,673
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
353,135
|
|
|
784,808
|
| ||||||||||||||||||||||||||||||||||||||||||||
|
| 2020
|
|
| 302,404
|
|
| —
|
|
| 7,430,000
|
|
| 170,000
|
|
| 15,892
|
|
| 7,918,296
|
| |||||||||||||||||||||||||||||||||||||||||||||
|
| 2019
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
| |||||||||||||||||||||||||||||||||||||||||||||
| (1) |
|
| (2) | These bonus amounts represent the amounts earned for performance under the Company’s Annual Bonus Incentive Plan during calendar year |
| (3) | Amounts consist of 401(k) matching contribution, as well as life insurance premiums for the benefit of each executive officer. |
| (4) | The amounts reported for Christopher Anzalone in the Stock Awards column reflect the grant date fair value of a January 2021 restricted stock unit award that is subject to vesting upon the achievement of specific performance conditions, as described above in the Compensation Discussion and Analysis. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $23,019,000 based on this evaluation. If we had determined that as of the date of the grant it was probable that 100% of the performance conditions would be achieved, we would have assigned a grant date fair value of $61,384,000 for the restricted stock units. The amounts reported in the Summary Compensation Table for these awards may not represent the amounts that Christopher Anzalone will realize from the awards. Whether, and to what extent, an NEO realizes value will depend on our actual operating performance, stock price fluctuations and the NEO’s continued employment. Additionally, in December 2021, these awards were modified to change the vesting to be subject entirely based on market capitalization-based thresholds rather than performance conditions. This modification did not result in any incremental fair value associated with the award. |
| 38 | |
2022 PROXY STATEMENT Executive Compensation
| (5) | The amounts reported for Christopher Anzalone in the Stock Awards column reflect the grant date fair value of a January 2020 restricted stock unit award that is subject to vesting upon the achievement of specific performance conditions, as described above in the Compensation and Analysis. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $12,686,000 based on this evaluation. If we had determined that as of the date of the grant it was probable that 100% of the performance conditions would be achieved, we would have assigned a grant date fair value of $57,087,000 for the restricted stock units. The amounts reported in the Summary Compensation Table for these awards may not represent the amounts that Christopher Anzalone will realize from the awards. Whether, and to what extent, an NEO realizes value will depend on our actual operating performance, stock price fluctuations and the NEO’s continued employment. Additionally, in December 2021, these awards were modified to add an additional vesting requirement related to market capitalization. This modification did not result in any incremental fair value associated with the award. |
| (6) | The amounts reported for Christopher Anzalone in the Stock Awards column reflect the grant date fair value of a January 2019 restricted stock unit award that is subject to vesting upon the achievement of specific performance conditions, as described above in the Compensation Discussion and Analysis. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $0 based on this evaluation. If we had determined that as of the date of the grant it was probable that 100% of the performance conditions would be achieved, we would have assigned a grant date fair value of $7,452,000 for the restricted stock units. The amounts reported in the Summary Compensation Table for these awards may not represent the amounts that Christopher Anzalone will realize from the awards. Whether, and to what extent, |
|
| (8) | Mr. Hassard’s employment with us began in |
|
20202022 PROXY STATEMENT Executive Compensation
|
|
Fiscal 2021 Grants of Plan Based Awards Table
The following table sets forth cash bonus and equity grants made to the named executive officersNEOs in fiscal 2019:2021:
| Estimated Future Payouts UnderNon-Equity Incentive Plan Awards (1) |
Estimated Future Payouts | All Other Stock Awards: Number of Shares of Stock or Units (#) (3) | Grant Date Fair | Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1) |
Estimated Future Payouts | All Other Stock Awards: Number of Shares of Stock or Units (#) (3) | Grant Date Fair | |||||||||||||||||||||||||||||||||||||||||||
Name | Grant Date | Target | Target | Grant Date | Target | Target | ||||||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
| $
| 682,500
|
|
| —
|
|
| —
|
|
| —
|
|
| $845,000
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||
PRSUs
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
| $
| 7,673,000
|
| |||||||||||||||||||||||||||||||||||
PRSUs
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
| $
| 7,673,000
|
| |||||||||||||||||||||||||||||||||||
PRSUs
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
| $
| 7,673,000
|
| |||||||||||||||||||||||||||||||||||
PRSUs (4)
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
|
| —
|
| |||||||||||||||||||||||||||||||||||
PRSUs (4)
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
|
| —
|
| |||||||||||||||||||||||||||||||||||
PRSUs (4)
|
| 1/1/2019
|
|
| —
|
|
| 200,000
|
|
| —
|
|
| —
|
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
|
| —
|
| ||||||||||||||||||||
PRSUs (4)
|
| 1/1/2019
|
|
| —
|
|
| 200,000
|
|
| —
|
|
| —
|
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
|
| —
|
| ||||||||||||||||||||
PRSUs (4)
|
| 1/1/2019
|
|
| —
|
|
| 200,000
|
|
| —
|
|
| —
|
|
| 1/1/2021
|
|
| —
|
|
| 100,000
|
|
| —
|
|
| —
|
| ||||||||||||||||||||
Kenneth Myszkowski
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
| $
| 193,500
|
|
| —
|
|
| —
|
|
| —
|
|
| $220,163
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||
RSUs
|
| 1/1/2019
|
|
| —
|
|
| —
|
|
| 85,000
|
| $
| 1,055,700
|
|
| 1/1/2021
|
|
| —
|
|
| —
|
|
| 60,000
|
| $
| 4,603,800
|
| ||||||||||||||||||||
Bruce D. Given
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
| $
| 350,000
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||||||||||||||
RSUs
|
| 1/1/2019
|
|
| —
|
|
| —
|
|
| 210,000
|
| $
| 2,608,200
|
| |||||||||||||||||||||||||||||||||||
Patrick O’Brien
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
| $
| 191,880
|
|
| —
|
|
| —
|
|
| —
|
|
| $217,845
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||
RSUs
|
| 1/1/2019
|
|
| —
|
|
| —
|
|
| 70,000
|
| $
| 869,400
|
|
| 1/1/2021
|
|
| —
|
|
| —
|
|
| 60,000
|
| $
| 4,603,800
|
| ||||||||||||||||||||
Zhen Li
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Javier San Martin
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
| $
| 156,000
|
|
| —
|
|
| —
|
|
| —
|
|
| $185,400
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||
RSUs
|
| 1/1/2019
|
|
| —
|
|
| —
|
|
| 75,000
|
| $
| 931,500
|
|
| —
|
|
| —
|
|
| —
|
|
| —
|
| |||||||||||||||||||||||
James Hamilton
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
|
| $194,670
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||||||||||||||
RSUs
|
| 1/1/2021
|
|
| —
|
|
| —
|
|
| 50,000
|
| $
| 3,836,500
|
| |||||||||||||||||||||||||||||||||||
James Hassard (5)
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Cash Bonus
|
| —
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||||||||||||||
RSUs
|
| —
|
|
| —
|
|
| —
|
|
| —
|
| ||||||||||||||||||||||||||||||||||||||
| (1) | Amounts listed represent cash award targets for our |
| (2) | These RSU and PRSU |
| (3) | RSUs have various vesting parameters. The RSUs granted in |
| (4) | We determined that as of the date of the grant it was not probable as defined under applicable accounting guidance that any of the performance vesting conditions for these PRSU awards would be achieved and assigned a grant date fair value of $0 based on this evaluation. |
| (5) | Mr. Hassard’s employment with us was terminated in August 2021. Under his fiscal 2021 compensation arrangements Mr. Hassard had the opportunity to receive an incentive cash bonus of 40% of his base salary. |
|
20202022 PROXY STATEMENT Executive Compensation
Fiscal 2021 Outstanding Equity Awards at Fiscal Year End Table
The following table provides information, with respect to the Named Executive Officers,NEOs, concerning the outstanding equity awards covering shares of the Company’s common stock as of September 30, 2019.2021.
| Option Awards | Stock Awards | Option Awards | Stock Awards | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Name | Grant Date | Number of Securities Underlying Unexercised Options (# Exercisable) (1) | Number of Securities Underlying Unexercised Options (# Unexercisable) | Option Exercise Price ($) | Option Expiration Date | Number of That (#) (3) | Market Value of Shares or That Not ($) (4) | Equity That Not (#) (2) | Equity Value That Not | Grant Date | Number of Securities Underlying Unexercised Options (# Exercisable) (1) | Number of Securities Underlying Unexercised Options (# Unexercisable) | Option Exercise Price ($) | Option Expiration Date | Number of That (#) (3) | Market Value of Shares or That Not ($) (4) | Equity That Not (#) (2) | Equity Value That Not | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone | 3/4/2010 | 56,325 | — | 5.20 | 3/4/2020 | — | — | — | — | 10/21/2011 | 15,000 | — | 4.60 | 10/21/2021 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8/16/2010 | 50,000 | — | 9.90 | 8/16/2020 | — | — | — | — | 2/16/2012 | 170,000 | — | 5.19 | 2/16/2022 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10/21/2011 | 15,000 | — | 4.60 | 10/21/2021 | — | — | — | — | 9/28/2012 | 40,624 | — | 2.62 | 9/28/2022 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/16/2012 | 170,000 | — | 5.19 | 2/16/2022 | — | — | — | — | 5/6/2013 | 104,928 | — | 2.01 | 5/6/2023 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9/28/2012 | 40,624 | — | 2.62 | 9/28/2022 | — | — | — | — | 9/21/2013 | 57,755 | — | 4.75 | 9/21/2023 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5/6/2013 | 159,928 | — | 2.01 | 5/6/2023 | — | — | — | — | 2/6/2014 | 60,000 | — | 14.54 | 2/6/2024 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9/21/2013 | 69,991 | — | 4.75 | 9/21/2023 | — | — | — | — | 3/6/2015 | 300,000 | — | 7.75 | 3/6/2025 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/6/2014 | 60,000 | — | 14.54 | 2/6/2024 | — | — | — | — | 1/1/2016 | 51,726 | — | 6.15 | 1/1/2026 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3/6/2015 | 300,000 | — | 7.75 | 3/6/2025 | — | — | — | — | 1/1/2020 | — | — | — | — | — | — | 900,000 | 56,187,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2016 | 73,333 | 6,667 | 6.15 | 1/1/2026 | — | — | — | — | 1/1/2021 | — | — | — | — | — | — | 800,000 | 49,944,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2018 | — | — | — | — | — | — | 333,333 | 6,389,994 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2019 | — | — | — | — | — | — | 600,000 | 16,908,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kenneth Myszkowski | 8/16/2010 | 12,000 | — | 9.90 | 8/16/2020 | — | — | — | — | 1/1/2018 | — | — | — | — | 18,750 | 1,170,563 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/16/2012 | 48,000 | — | 5.19 | 2/16/2022 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/6/2014 | 50,000 | — | 14.54 | 2/6/2024 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3/6/2015 | 50,000 | — | 7.75 | 3/6/2025 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2016 | 36,666 | 3,334 | 6.15 | 1/1/2026 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2018 | — | — | — | — | 56,250 | 1,585,125 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2019 | — | — | — | — | 85,000 | 2,395,300 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bruce D. Given | 10/26/2011 | 30,000 | — | 5.20 | 10/26/2021 | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/16/2012 | 110,000 | — | 5.19 | 2/16/2022 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9/21/2013 | 40,000 | — | 4.75 | 9/21/2023 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2/6/2014 | 50,000 | — | 14.54 | 2/6/2024 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3/6/2015 | 60,000 | — | 7.75 | 3/6/2025 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2016 | 55,000 | 5,000 | 6.15 | 1/1/2026 | — | — | — | — | 1/1/2019 | — | — | — | — | 42,500 | 2,653,275 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2018 | — | — | — | — | 131,250 | 3,698,625 | — | — | 1/1/2020 | — | — | — | — | 63,750 | 3,979,913 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2019 | — | — | — | — | 210,000 | 5,917,800 | — | — | 1/1/2021 | — | — | — | — | 60,000 | 3,745,800 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Patrick O’Brien | 12/2/2014 | 90,000 | — | 5.22 | 12/2/2024 | — | — | — | — | 1/1/2016 | 60,000 | — | 6.15 | 1/1/2026 | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2016 | 55,000 | 5,000 | 6.15 | 1/1/2026 | — | — | — | — | 1/1/2018 | — | — | — | — | 15,000 | 936,450 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2018 | — | — | — | — | 45,000 | 1,268,100 | — | — | 1/1/2019 | — | — | — | — | 35,000 | 2,185,050 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2019 | — | — | — | — | 70,000 | 1,972,600 | — | — | 1/1/2020 | — | — | — | — | 52,500 | 3,277,575 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zhen Li (5) | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2021 | — | — | — | — | 60,000 | 3,745,800 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Javier San Martin | 11/18/2019 | — | — | — | — | 112,500 | 7,023,375 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
James Hamilton | 1/1/2018 | — | — | — | — | 12,500 | 780,375 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2019 | — | — | — | — | 30,000 | 1,872,900 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2020 | — | — | — | — | 33,750 | 2,107,013 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1/1/2021 | — | — | — | — | 50,000 | 3,121,500 | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
James Hassard (5) | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (1) | Options are priced at the market closing price on the date of grant. Options have various vesting parameters, but generally vest within 48 months after the award is granted. |
|
2020 PROXY STATEMENT Executive Compensation
| (2) | The amounts reported for Christopher Anzalone in this column reflect the January |
| (3) | Restricted stock units have various vesting parameters but generally vest in four equal annual installments beginning 1 year from the grant date. |
| (4) | Value is based on |
| (5) |
|
| 41 |
2022 PROXY STATEMENT Executive Compensation
Fiscal 2021 Options ExercisedExercises and Stock Vested Table
The following table provides information, with respect to the Named Executive Officers,NEOs, concerning options exercised or RSUs or PRSUs vested during fiscal 2019.2021.
| Option Awards | Stock Awards | Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||
| Name |
Number of Shares | Value Realized on Exercise (1) | Number of Shares Acquired on Vesting | Value Realized on Vesting (2) |
Number of Shares | Value Realized on Exercise (1) | Number of Shares Acquired on Vesting | Value Realized on Vesting (2) | ||||||||||||||||||||||||||||
Christopher Anzalone |
| 162,098 |
| 3,723,993 |
| 523,000 | $ | 7,425,050 | 95,510 | 6,712,408 | 200,000 | 11,712,000 | ||||||||||||||||||||||||
Kenneth Myszkowski |
| 43,000 |
| 759,456 |
| 180,417 | $ | 2,602,667 | 72,671 | 3,782,190 | 61,250 | 4,448,588 | ||||||||||||||||||||||||
Bruce D. Given |
| 206,000 |
| 3,528,708 |
| 473,750 | $ | 6,429,238 | ||||||||||||||||||||||||||||
Patrick O’Brien |
| — |
| — |
| 160,000 | $ | 2,323,200 | 90,000 | 7,491,114 | 50,000 | 3,631,500 | ||||||||||||||||||||||||
Zhen Li |
| 146,041 |
| 1,331,278 |
| 101,250 | $ | 1,439,775 | ||||||||||||||||||||||||||||
Javier San Martin | — | — | 37,500 | 2,563,500 | ||||||||||||||||||||||||||||||||
James Hamilton | — | — | 38,750 | 2,899,663 | ||||||||||||||||||||||||||||||||
James Hassard | — | — | 31,250 | 2,324,375 | ||||||||||||||||||||||||||||||||
| (1) | Value is calculated as the price of |
| (2) | Value is calculated as the price of |
Termination Benefits — Potential Payments Upon Termination or Change in Control
The Company has the following severance or change of control arrangements with its Named Executive Officers:NEOs:
Dr. Anzalone’s employment agreement with the Company provides that, if the Company terminates Dr. Anzalone’s employment without Cause or if Dr. Anzalone terminates his employment for Good Reason, on his date of termination, Dr. Anzalone will receive aone-time lump sum payment equal to the sum of: (i) one month of base salary and (ii) premiums for 30thirty (30) days of medical and dental benefits. To receive such payments Dr. Anzalone is required to execute a general release in favor of the Company.
For purposes of Dr. Anzalone’s employment agreement:
“Cause” means (i) the conviction (by trial or upon a plea of nolo contendere) of a felony or other crime involving moral turpitude or the commission of any other material act or omission involving dishonesty, disloyalty or fraud with respect to the Company or any of its subsidiaries or any of their customers or suppliers, (ii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company or any of its subsidiaries substantial public disgrace or disrepute or economic harm, (iii) the engaging of gross misconduct and the failure to cease such conduct and rectify any harm to the Company resulting therefrom within 30 days after written demand therefor by the Company identifying with reasonable particularity such conduct and harm, or (iv) any other material breach of the employment agreement by Executive and the failure to cease such breach and rectify any harm to the Company within 30 days after written demand by the Company identifying with reasonable particularity such breach and harm; and
“Good Reason” means (i) Executive’s duties, responsibilities, titles or offices are diminished as compared to those described in the employment agreement without Executive’s written consent, and the Company fails to reinstate such duties, responsibilities, titles or offices within 30 days after written demand by Executive identifying with reasonable particularity the diminishment, (ii) the relocation of Executive’s base office to an office that is more than thirty (30) highway miles from Pasadena, CA, (iii) the failure of the Company to obtain a satisfactory agreement from any successor to assume and agree to perform the obligations under the employment agreement and (iv) any other material breach of this employment agreement by the Company and the failure to cease such breach and rectify any harm to Executive resulting within 30 days after written demand by Executive identifying with reasonable particularity the breach and harm.
Pursuant to his offer of employment by the Company, Mr. Myszkowski is entitled to severance pay equal to three months’ base salary plus an amount equal to the premiums on his medical and dental benefits for the same period upon termination of his employment without cause.
|
2020 PROXY STATEMENT Executive Compensation
Pursuant to his offer of employment by the Company, Mr. O’Brien is entitled to severance pay equal to six months’ base salary upon a qualifying termination of his employment without causecase only upon change of control as defined in the Company’s 2013 Incentive Plan.
| 42 | |
2022 PROXY STATEMENT Executive Compensation
The Company has not entered into a severance arrangement with Dr. Given.San Martin or Dr. Hamilton. Mr. Hassard’s employment was terminated in August 2021 and the Company entered into a severance agreement with Mr. Hassard whereby he received a lump sum payment of $335,608.
Additionally, pursuant to the 2004 Equity Incentive Plan and the 2013 Incentive Plan, any unvested awards held by plan participants, including the Named Executive Officers,NEOs, become fully vested upon a change of control, except as otherwise determined by the Board and except with respect to the outstanding awards held by the CEO whose awards will only become fully vested upon a qualifying termination of employment following a change of control.
The following tables set forth information regarding potential termination and change of control arrangements with our executive officers had their employment been terminated or a change in control of the Company taken place on September 30, 2019:2021:
Termination Payments
| Triggering Event | Salary ($) | Benefits ($) | Stock Awards (1)($) | Option Awards (1)($) | Total | Salary ($) | Benefits ($) | Stock Awards (1)($) | Option Awards (1)($) | Total | ||||||||||||||||||||||||||||||
Termination by Employer without Cause | ||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone (2) |
| 56,875 |
|
| 1,888 |
|
| — |
|
| — |
|
| 58,673 |
|
| 70,417 |
|
| 2,307 |
|
| — |
|
| — |
|
| 72,724 | |||||||||||
Kenneth Myszkowski |
| 107,500 |
|
| 8,619 |
|
| — |
|
| — |
|
| 116,119 |
|
| 122,313 |
|
| 10,203 |
|
| — |
|
| — |
|
| 132,516 | |||||||||||
Bruce D. Given |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
Patrick O’Brien |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| ||||||||||
Zhen Li (3) |
| N/A |
|
| N/A |
|
| N/A |
|
| N/A |
|
| N/A |
| |||||||||||||||||||||||||
Javier San Martin |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
James Hamilton |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
James Hassard (3) |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
Change in Control | ||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone (2) |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
Kenneth Myszkowski |
| 122,313 |
|
| 10,203 |
|
| 11,549,550 |
|
| — |
|
| 11,682,066 | ||||||||||||||||||||||||||
Patrick O’Brien |
| — |
|
| — |
|
| 10,144,875 |
|
| — |
|
| 10,144,875 | ||||||||||||||||||||||||||
Javier San Martin |
| — |
|
| — |
|
| 7,023,375 |
|
| — |
|
| 7,023,375 | ||||||||||||||||||||||||||
James Hamilton |
| — |
|
| — |
|
| 7,881,788 |
|
| — |
|
| 7,881,788 | ||||||||||||||||||||||||||
James Hassard (3) |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
| |||||||||||||||||||||||||
Involuntary Termination Following a Change in Control | ||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone |
| — |
|
| — |
|
| — |
|
| — |
|
| — |
|
| 70,417 |
|
| 2,307 |
|
| 106,131,000 |
|
| — |
|
| 106,203,874 | |||||||||||
Kenneth Myszkowski |
| 107,500 |
|
| 8,619 |
|
| 3,980,425 |
|
| 73,448 |
|
| 4,169,992 |
| |||||||||||||||||||||||||
Bruce D. Given |
| — |
|
| — |
|
| 9,616,425 |
|
| 110,150 |
|
| 9,726,575 |
| |||||||||||||||||||||||||
Patrick O’Brien |
| — |
|
| — |
|
| 3,240,700 |
|
| 110,150 |
|
| 3,350,850 |
|
| 242,050 |
|
| — |
|
| — |
|
| — |
|
| 242,050 | |||||||||||
Zhen Li (3) |
| N/A |
|
| N/A |
|
| N/A |
|
| N/A |
|
| N/A |
| |||||||||||||||||||||||||
Involuntary Termination Following a Change in Control | ||||||||||||||||||||||||||||||||||||||||
Christopher Anzalone |
| 56,875 |
|
| 1,888 |
|
| 26,301,324 |
|
| 146,874 |
|
| 26,506,961 |
| |||||||||||||||||||||||||
Patrick O’Brien |
| 213,200 |
|
| — |
|
| — |
|
| — |
|
| 213,200 |
| |||||||||||||||||||||||||
| (1) | For stock awards the value is calculated as the number of unvested shares multiplied by the Company’s closing stock price at September 30, |
| (2) | Dr. Anzalone’s employment contract also provides for payment of the values set forth above upon his resignation for “good reason” as defined in his employment agreement. |
| (3) |
|
CEO Pay Ratio
Pursuant to Item 402(u) of RegulationS-K, we are required to calculate and disclose the median of the annual total compensation of all of our employees (excluding our CEO, Dr. Anzalone), the annual total compensation of Dr. Anzalone, and the ratio of these two amounts.
|
20202022 PROXY STATEMENT Executive Compensation
Based on the fact that we had a significant number of new hires during fiscal 2021, we did not elect to use the same median employee as the prior year. Our median employee was identified using the entire population of our employees as of September 30, 20192021 based on a consistently applied compensation measure, (“or CACM,”), that reasonably reflects the annual compensation of our employees. The CACM selected by us for our disclosure included annual base salary, overtime for theyear-to-date period ended September 30, 2019, the cash bonus amount for fiscal 2019,2021, the grant-date fair value for stock-based awards (calculated in accordance with requirements for the Summary Compensation Table), and welfare and health benefits for fiscal 2019.2021.
Based on the CACM methodology described above, we identified the median employee and calculated the 2019fiscal 2021 compensation for this selected employee in the same manner we determine the annual total compensation of our Named Executive OfficersNEOs for purposes of the Summary Compensation Table. The median employeeof the annual total compensation is $179,403.of all our employees was $168,720. Dr. Anzalone’s 2019fiscal 2021 annual total compensation as disclosed in the Fiscal 2021 Summary Compensation Table is $2,216,264.was $24,703,855. As a result, our CEO to median employee pay ratio for 2018fiscal 2021 is 12:146:1. This represents an increase from the 2020 ratio of 48:1 primarily due to the PRSU awards granted to Dr. Anzalone that were deemed probable of achievement at the grant date, in accordance with ASC 718.
This pay ratio is a reasonable estimate calculated by a method consistent with the SEC requirements, described above, based on our payroll and employment records. As a result of a variety of factors, including employee populations, potential differences in the components used for the CACM, compensation philosophies and certain assumptions, pay ratios reported by other companies may not be comparable to our pay ratio. The pay ratio is not utilized by our management or our compensation committee for compensation-related decisions.
|
20202022 PROXY STATEMENT Proposal Four — Ratification of Appointment of Independent Auditors
Proposal Four — Ratification of Appointment of Independent Auditors
Our Audit Committee, with the ratification of our Board, selected the accounting firm of Rose, Snyder & Jacobs, LLP (“RS&J”) as the Company’s independent auditors for the fiscal year ending September 30, 2020,2022, and that selection is now being submitted to the stockholders.
A representative of RS&J willis expected to be available at the Annual Meeting to respond to appropriate stockholder questions or make any other statements such representative deems appropriate.
Stockholders are not required to ratify the appointment of RS&J as our independent auditor. However, we are submitting the appointment for ratification as a matter of good corporate practice. If stockholders fail to ratify the appointment, the Audit Committee will consider whether or not to retain RS&J. Even if the appointment is ratified, the Audit Committee may direct the appointment of a different independent auditor at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders.
Vote Required; Recommendation of the Board
In order to be ratified, Proposal Four must be approved by a majority ofthe Required Vote, assuming a quorum is present. For this purpose, abstentions will be counted as a vote against the proposal.
|
|
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE“FOR” PROPOSAL FOUR. |
|
20202022 PROXY STATEMENT Audit Fees
The Audit Committee regularly reviews and determines whether specific projects or expenditures with our independent auditors, RS&J, may potentially affect their independence. The Audit Committee’s policy is topre-approve all audit and permissiblenon-audit services provided by RS&J.Pre-approval is generally provided by the Audit Committee for up to one year, detailed to the particular service or category of services to be rendered and is generally subject to a specific budget. The Audit Committee may alsopre-approve additional services of specific engagements on acase-by-case basis. All engagements of our independent registered public accounting firm in 20192021 and 20182020 werepre-approved by the audit committee.
The following table sets forth the aggregate audit fees invoicedbilled and expected to be billed by RS&J for the indicated fiscal years ended September 30, 2019year and September 30, 2018:the fees billed by RS&J for all other services rendered during the indicated fiscal year:
| Year Ended September 30, | ||||||||||||||||||
| Year Ended September 30, | 2021 | 2020 | ||||||||||||||||
| 2019 | 2018 | |||||||||||||||||
Audit fees (1) | $ | 231,325 | $ | 194,000 | $ | 295,400 | $ | 226,000 | ||||||||||
Audit-related fees (2) | 17,000 | 59,500 | 70,250 | 163,000 | ||||||||||||||
Tax Fees | — | — | — | — | ||||||||||||||
All other fees | — | — | — | — | ||||||||||||||
Total | $ | 248,325 | $ | 253,500 | $ | 365,650 | $ | 389,000 | ||||||||||
| (1) | Fees invoiced by RS&J includeyear-end audit and periodic reviews of Forms10-Q and10-K. |
| (2) | Fees invoiced by RS&J related to Comfort Letters and Consents for financings and registration statements, and other agreed-upon procedures. |
|
20202022 PROXY STATEMENT Report of the Audit Committee
The following is the report of the Audit Committee with respect to the Company’s audited financial statements for fiscal 2019,2021, which include the consolidated balance sheets of the Company as of September 30, 20192021 and September 30, 2018,2020, and the related consolidated statements of operations, stockholders’ equity and cash flows for the fiscal years ended September 30, 2019,2021, September 30, 20182020 and September 30, 2017,2019, and the notes thereto.
Composition. At September 30, 2019, The2021, the Audit Committee of the Board was comprised of threefive directors and operates under a written charter adopted by the Board. The members of the Audit Committee were William Waddill, Marianne De Backer, Mauro Ferrari, Adeoye Olukotun and Michael S. Perry. All members of the Audit Committee were “independent,” as defined in Rule10A-3 under the Exchange Act and Rule 5605(c) of the Nasdaq Marketplace Rules, and are financially literate.
Responsibilities. The responsibilities of the Audit Committee include engaging an accounting firm as the Company’s independent registered public accounting firm. Management has primary responsibility for the Company’s internal controls and financial reporting process. The independent registered public accounting firm is responsible for performing an independent audit of the Company’s consolidated financial statements in accordance with generally accepted auditing standards and for issuing a report thereon. The Audit Committee’s responsibility is to oversee these processes.
Review with Management and independent registered public accounting firm. On November 18, 2019,19, 2021, the Audit Committee consisted of William Waddill, Marianne De Backer, Mauro Ferrari, Adeoye Olukotun and Michael S. Perry. On that date, the Audit Committee met separately to review the Company’s consolidated audited financial statements and held discussions with management and RS&J. Management represented to the Audit Committee that the Company’s consolidated financial statements were prepared in accordance with generally accepted accounting principles. The members of the Audit Committee discussed with RS&J matters required to be discussed under the applicable standards of the Public Company Accounting Oversight Board. The Company’s independent registered public accounting firm also provided to the Audit Committee the written disclosures and the letter required by the Public Company Accounting Oversight Board regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence and the Audit Committee discussed the firm’s independence with RS&J.
Conclusion. Based upon the Audit Committee’s review of the financial statements and discussions with management and RS&J, the Audit Committee’s review of the representations of management and the report of RS&J to the Audit Committee, the Audit Committee recommended that the Board include the audited consolidated financial statements in the Company’s Annual Report on Form10-K for the fiscal year ended September 30, 2019,2021, as filed with the SEC.
This report is submitted by the Audit Committee of the Board.
William Waddill, ChairmanCommittee Chair
Marianne De Backer
Mauro Ferrari
Adeoye Olukotun
Michael S. Perry
|
20202022 PROXY STATEMENT Voting Securities of Principal Stockholders and Management
Voting Securities of Principal Stockholders and Management
The following table sets forth the beneficial ownership of the Company’s Common Stock as of January 14, 2020,10, 2022, by (i) each of the named executive officersNEOs named in the table under “Executive Compensation and Related Information,” (ii) each director, (iii) all current directors and executive officers as a group, and (iv) the holders of greater than 5% of our total shares outstanding known to us. Unless otherwise specified in the footnotes to the table below, the persons and entities named in the table have sole voting and investment power with respect to all shares beneficially owned, subject to community property laws, where applicable, and the address of each stockholder is c/o Arrowhead Pharmaceuticals, Inc., 177 E. Colorado Blvd, Suite 700, Pasadena, CA, 91105 unless otherwise indicated.
Number and Percentage of Shares
| ||||||||||||||||||||
Number and Percentage of Shares
|
Shares
|
Percentage
| ||||||||||||||||||
Shares
|
Percentage
| |||||||||||||||||||
5% Beneficial Owners
|
|
| ||||||||||||||||||
BlackRock Inc (2) 55 East 52nd Street, New York, NY 10055
|
| 14,869,280
|
|
| 14.6
| %
| 12,563,132 | 12.2 | % | |||||||||||
The Vanguard Group (3) 100 Vanguard Blvd., Malvern, PA 19355
|
| 10,844,571
|
|
| 10.7
| %
| 9,281,551 | 9.0 | % | |||||||||||
Executive Officers and Directors
| ||||||||||||||||||||
Named Executive Officers and Directors |
|
| ||||||||||||||||||
Christopher Anzalone (4)
|
|
2,350,780
|
|
|
2.3
|
%
| 2,519,055 | 2.4 | % | |||||||||||
Kenneth Myszkowski (5)
|
|
354,402
|
|
|
*
|
| ||||||||||||||
Bruce D. Given (6)
|
|
713,993
|
|
|
*
|
| ||||||||||||||
Patrick O’Brien (7)
|
|
255,875
|
|
|
*
|
| ||||||||||||||
Kenneth Myszkowski | 295,255 | * | ||||||||||||||||||
Patrick O’Brien | 191,375 | * | ||||||||||||||||||
Javier San Martin | 36,000 | * | ||||||||||||||||||
James Hamilton | 25,625 | * | ||||||||||||||||||
Douglass Given
|
|
172,925
|
|
|
*
|
| 136,243 | * | ||||||||||||
Michael S. Perry (8)
|
|
113,000
|
|
|
*
|
| ||||||||||||||
Mauro Ferrari (9)
|
|
26,900
|
|
|
*
|
| ||||||||||||||
Michael S. Perry | 85,500 | * | ||||||||||||||||||
Mauro Ferrari | 36,751 | * | ||||||||||||||||||
William Waddill
|
|
46,500
|
|
|
*
|
| 25,750 | * | ||||||||||||
Marianne De Backer
|
|
—
|
|
|
*
|
| 17,000 | * | ||||||||||||
All Executive Officers and Directors as a group (9 persons) (10)
|
|
4,034,375
|
|
|
4.0
|
%
| ||||||||||||||
Adeoye Olukotun | 4,950 | * | ||||||||||||||||||
All Executive Officers and Directors as a group (11 persons) | 3,373,324 | 3.2 | % | |||||||||||||||||
| * | Less than 1% |
| (1) | Based on |
| (2) | Based on |
| (3) | Based on Amendment No. 2 to Schedule 13G/A filed February 10, 2021. According to Amendment No. 2, The Vanguard Group has sole voting power and sole dispositive power over |
|
| (4) | Includes |
|
|
|
|
|
|
|
20202022 PROXY STATEMENT Equity Compensation Plan Information
Equity Compensation Plan Information
The following table provides information as of September 30, 20192021 with respect to shares of our Common Stock that may be issued under our equity compensation plans.
Equity Compensation Plan Information
| ||||||||||||||||||||||||||||||
Equity Compensation Plan Information
|
Number of be Issued exercise of options, and rights
|
Weighted
|
Number of
| |||||||||||||||||||||||||||
Number of be Issued exercise of options, and rights
|
Weighted
|
Number of
| ||||||||||||||||||||||||||||
Equity compensation plans approved by security holders (1)
|
|
5,984,992
|
|
$
|
7.00
|
|
|
341,294
|
| 5,728,524 | $ | 13.09 | 8,013,790 | |||||||||||||||||
Equity compensation plans not approved by security holders (2)
|
|
851,511
|
|
$
|
13.57
|
|
|
—
|
| 1,559,565 | $ | 36.59 | — | |||||||||||||||||
Total
|
|
6,836,503
|
|
$
|
8.16
|
|
|
341,294
|
| 7,288,089 | $ | 19.60 | 8,013,790 | |||||||||||||||||
| (1) | Includes options outstanding representing |
| (2) | Includes |
Current Executive Officers of the Registrant
The names, ages and positions of our current executive officers serving as of January 14, 202010, 2022 are provided below. Biographical information regarding these officers is set forth under the following table, except for Dr. Anzalone, whose biography is set forth above with our other directors.
Name
|
Age
|
Position with Arrowhead
| ||
Christopher Anzalone |
| Chief Executive Officer & President and Director | ||
Kenneth A. Myszkowski | 55 | Chief Financial Officer | ||
Javier San Martin | 56 | Chief Medical Officer | ||
James Hamilton |
| Senior Vice President, Discovery and Translational Medicine | ||
Patrick O’Brien |
|
| ||
|
| General Counsel, Corporate Secretary, and Chief Compliance Officer | ||
Kenneth A. Myszkowski, Chief Financial Officer, joined the Company in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for twostart-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which providedon-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.
|
20202022 PROXY STATEMENT Equity Compensation Plan Information
Dr. Bruce Given, Chief Operating Officer, joined the Company in 2011. Dr. Given was a member of the board of directors for ICON, plc. from 2004 until his retirement in 2013 and Chairman of its Board of Directors from 2010 to 2013. Dr. Given served as the President and Chief Executive Officer, and as a member of the board of directors of Encysive Pharmaceuticals, anR&D-based commercial pharmaceutical company, roles he held from 2002 through 2007. Subsequent to his tenure at Encysive until 2011, Dr. Given was President of Bruce Given Consulting, a firm that provides consulting services to biotech companies. Since October 1, 2009, Dr. Given has been a director of Calando Pharmaceuticals, Inc., and from February 2010 until its dissolution in October 2014, Dr. Given was the Chief Executive Officer of Leonardo Biosystems, Inc., in which Arrowhead held a minority equity interest. Prior to his tenure at Encysive, Dr. Given held several senior executive roles at Johnson & Johnson, Sandoz Pharmaceuticals and Schering-Plough. Dr. Given obtained his bachelor of sciences degree from Colorado State University, graduating Phi Beta Kappa. He received his M.D. degree with honors from the University of Chicago, Pritzker School of Medicine and completed his medical training at the University of Chicago and at Brigham and Women’s Hospital in Boston, where he was a Clinical Fellow at Harvard Medical School. He is board certified in internal medicine and endocrinology and metabolism and has authored 33 scientific publications. Dr. Bruce Given is a brother of Dr. Douglass Given, a director of the company.
Patrick C. O’Brien, General Counsel, Corporate Secretary, and Chief Compliance Officer, joined the Company in December 2014. Mr. O’Brien has practiced in the healthcare legal field for over 25 years. Before joining the Company, from 2012 to 2014, Mr. O’Brien was with Shire, as global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland & Knight LLP in its Washington, DC office. In 2010, Mr. O’Brienco-founded the law firm O’Brien Gould PLLC which joined Holland & Knight in 2011. From 2009 to 2010, Mr. O’Brien was a partner in Burke O’Neil LLC. From 2001 to 2009, Mr. O’Brien served in several legal roles with Johnson & Johnson, including serving as Vice President of Law for J&J’s Centocor Ortho-Biotech unit. Mr. O’Brien previously served as Regulatory Counsel with the United States Food & Drug Administration. Mr. O’Brien was awarded a BS in Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona.
Dr. Curt Bradshaw,Chief Scientific Officer, joined the Company in November 2019. From 2018 to November 2019 Dr. Bradshaw was President, Chief Scientific Officer, and a member of the board of directors for Tollnine, a company heco-founded to develop novel antibody conjugates for immuno-oncology. From 2012 — 2019 he served as Chief Scientific Officer and a member of the board of directors of Solstice Biologics, where he managed and oversaw all company operations and research exploring novel siRNA technologies for the development of human therapeutics. Before Solstice, Dr. Bradshaw was Vice President of Research and Development and Chief Scientific Officer at Traversa Therapeutics. At Traversa, he had primary R&D oversight and was a key strategic contributor to internal technology development, business strategy, and oversaw research alliances with multiple major pharmaceutical collaborators. Prior to Traversa, Dr. Bradshaw spent 7 years at CovX Research, a cornerstone of the Pfizer, Inc. Bioinnovation and Biotherapeutics Center. Prior to CovX, he spent 4 years at Ligand Pharmaceuticals and was responsible for the chemical development of clinical-phase active pharmaceutical ingredients. Dr. Bradshaw started his career at Abbott Laboratories, where he spent 6 years as a Research Chemist, Senior Research Chemist, and Project Leader. He received a PhD. in Organic Chemistry from Texas A&M University.
Javier San Martin, Chief Medical Officer, joined the Company in November 2019. Dr. San Martin previously served as Senior Vice President and Head of Global Clinical Development at Ultragenyx from 2013 until November 2019. At Ultragenyx he led the development of burosumab, a novel drug for the treatment ofX-Linked Hypophosphatemia approved across major regions including the United States, the European Union, and Canada. Before his tenure at Ultragenyx, he served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals, where he was responsible for managing the medical, regulatory, and clinical operations group focused on early clinical programs. From 2006 to 2011, Dr. San Martin was a Global Development Leader at Amgen, Inc., where he was responsible for two major development programs. He directed the romosozumab clinical program through the end of phase II, and before that, was responsible for the development and approval of denosumab, the largest branded anti-osteoporosis treatment for postmenopausal osteoporosis and the first monoclonal antibody to address a very prevalent disease treated by primary care physicians. Prior to his time at Amgen, he spent seven years at Eli Lilly and Company, supporting late stage clinical development as well as medical affairs activities, including the successful launch of Evista and Forteo. He received his medical degree from the University of Buenos Aires Medical School and completed his residence in internal medicine at CEMIC University Hospital in Buenos Aires, Argentina, serving as Chief Resident, and, thereafter, as Attending Physician responsible for the internal medicine ward.
James Hassard,Hamilton, Chief Commercial Officer,Senior Vice President, Discovery & Translational Medicine, joined the Company in January 2020. Mr. Hassard served2014. He is responsible for target discovery as Senior Vice President of Marketingwell as non-clinical and Market Access at Coherus BioSciences since 2016, where he was instrumental in building the commercial organization and commercial capabilities. Heco-led the launch of Coherus’ first product, a biosimilar, pegfilgrastim; one of the most successful pharmaceutical launches of 2019. Prior to his tenure at Coherus, Mr. Hassardearly clinical development. Previously, Dr. Hamilton served as Vice President, Clinical Development, responsible for clinical strategy, clinical trial design and execution including early translational and mid-stage development of Marketingall Arrowhead programs. He is experienced in multiple disease areas including virology, hepatology, cardiovascular disease, rare disease and oncology. Dr. Hamilton led the clinical development of ARO-HBV (now JNJ-3989), which was licensed to Janssen Pharmaceuticals. In parallel, Dr. Hamilton served as Head of Corporate Development and led Arrowhead’s in-licensing transaction of Novartis’ RNAi assets, as well as the out-licensing of ARO-LPA (now AMG890) to Amgen and the ARO-AAT partnership with Takeda. Dr. Hamilton started his employment at Medivation, priorArrowhead as Medical Director and Head of Corporate development. He holds both MD and MBA degrees from The Ohio State University. He is a licensed physician and completed residency training with board certification in emergency medicine.
Delinquent Section 16(a) Reports
Under Section 16(a) of the Securities Exchange Act of 1934, the Company’s directors and officers and its significant stockholders (defined by statute as stockholders beneficially owning more than ten percent (10%) of the Common Stock) are required to file with the SEC reports of ownership, and throughchanges in ownership, of Common Stock. Based solely on a review of the reports filed with the SEC or representations that no form was required, the Company believes that, during the fiscal year ended September 30, 2021, all of its acquisition by Pfizer Pharmaceuticals. From 1999officers, directors and significant stockholders timely filed all required reports under Section 16(a), except that, due to administrative error, Patrick O’Brien disclosed late the transfer of 800 shares of Arrowhead stock donated on December 4, 2020, which was reported on a Form 4 filed on January 7, 2022.
|
2020 PROXY STATEMENT Equity Compensation Plan Information
2016, he held multiple increasingly senior commercial roles at Amgen, Inc., across sales and marketing, domestic and international, including an assignment as General Manager of Amgen Portugal. He was responsible for the launch, growth, and subsequent life-cycle management of several oncology and nephrology products, including darbepoetin alfa and cinacalcet. Prior to Amgen, Mr. Hassard spent several years at Schering-Plough Canada, in sales and marketing roles, in the therapeutic areas of oncology, cardiovascular and hepatitis. He received his Bachelor of Science in pharmacology from the University of Toronto and a master’s in business administration from Nova Southeastern University, Florida.
|
20202022 PROXY STATEMENT Review and Approval of Related-Party Transactions
Review and Approval of Related-Party Transactions
Our Board has adopted written policies and procedures for the review and approval of related-party transactions and has delegated to the Audit Committee the authority to review and approve the material terms of any proposed related-party transactions. To the extent that a proposed related-party transaction may involve anon-employee director or nominee for election as a director and may be material to a consideration of that person’s independence, the matter may also be considered by the other disinterested directors.
Pursuant to our Code of Business Conduct and Ethics and our Corporate Governance Committee Charter, each of our officers, directors and employees must disclose related-party transactions to our Board. In order to avoid conflicts of interest, our executive officers and directors may not acquire any ownership interest in any supplier, customer or competitor (other than nominal amounts of stock in publicly traded companies), enter into any consulting or employment relationship with any customer, supplier or competitor, or engage in any outside business activity that is competitive with any of our businesses, without first disclosing the proposed transaction. After the proposed transaction has been disclosed, a determination will be made by our Board or Audit Committee as to what course to follow, depending on the nature or extent of the conflict. Furthermore, our executive officers and directors may not serve on any board of directors of any customer, supplier or competitor unless such board service has been disclosed to us and approved by our Board.
In determining whether to approve or ratify a related-party transaction, the Board and/or Committee may consider, among other factors it deems appropriate, the potential benefits to us, the impact on a director’s or nominee’s independence or an executive officer’s relationship with or service to us, whether the related-party transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related party’s interest in the transaction. In deciding to approve a transaction, the Board or Audit Committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related party in connection with its approval of any transaction. Any transactions involving the compensation of executive officers, however, are reviewed and approved by the Compensation Committee. If a related-party transaction will be ongoing, the Audit Committee may establish guidelines to be followed in our ongoing dealings with the related party. Thereafter, the Audit Committee reviews and assesses the ongoing relationship with each related party to see that it is in compliance with the Audit Committee’s guidelines and that the related-party transaction remains appropriate.
| 51 |
20202022 PROXY STATEMENT Certain Relationships and Related Transactions, and Director Independence
Certain Relationships and Related Transactions, and Director Independence
As of September 30, 2019,2021, a majority of the members of the Board are independent directors, as defined by the Nasdaq Marketplace Rules. The Board has determined that all of the Company’s directors are independent, except Dr. Anzalone, the Company’s Chief Executive Officer, and Dr. Douglass Given, the brother of the Company’s former Chief Operating Officer.Non-employee directors do not receive consulting, legal or other fees from the Company, other than Board compensation.
Vincent Anzalone is the Company’s Vice President, Investor Relations and the brother of Christopher Anzalone, the Company’s CEO.Chief Executive Officer. Vincent Anzalone earned base salary and bonus of $273,560$300,810 during fiscal year 2019.2021. His current base salary is $244,860.$259,771. In January 2019,2021, Mr. Anzalone was awarded 40,00015,000 restricted stock units, and this award vests in four annual tranches from the grant date. The grant date fair value of this award is $496,800.$1,150,950.
Annual Report on Form10-K
The Company will mail, without charge to any stockholder upon written request, a copy of the Company’s Annual Report on Form10-K for the year ended September 30, 20192021 including the financial statements, schedules and a list of exhibits. Requests should be sent to Arrowhead Pharmaceuticals, Inc., 177 E. Colorado Blvd., Suite 700, Pasadena, CA 91105, Attn: Corporate Secretary, Phone(626) 304-3400.
Stockholders Sharing the Same Address
We may satisfy SEC rules regarding delivery of proxy statements including the proxy statement, annual report and Notice, by delivering a single Notice and, if applicable, a single set of proxy materials to an address shared by two or more of our stockholders. This delivery method can result in meaningful cost savings for us. To take advantage of this opportunity, we may deliver only one Notice, and if applicable, a single set of proxy materials to multiple stockholders who share an address, unless contrary instructions are received prior to the mailing date. Similarly, if you share an address with another stockholder and have received multiple copies of our Notice and/or other proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of these materials in the future. We undertake to deliver promptly upon written or oral request a separate copy of the Notice and/or other proxy materials to a stockholder at a shared address to which a single copy of these documents was delivered. If you hold stock as a record stockholder and prefer to receive separate copies of a Notice, and if applicable, other proxy materials either now or in the future, please contact us at the address provided below. If your stock is held through a brokerage firm or bank and you prefer to receive separate copies of a Notice and, if applicable, other proxy materials either now or in the future, please contact your brokerage firm or bank.
Arrowhead Pharmaceuticals, Inc.
177 E. Colorado Blvd., Suite 700
Pasadena CA 91105
Attn: Corporate Secretary
Phone(626) 304-3400
Other Matters
The Company knows of no other matters to be submitted at the Annual Meeting. If any other matters properly come before the meeting, it is the intention of the persons named in the proxy card to vote the shares they represent as the Board may recommend.
| BY ORDER OF THE BOARD OF DIRECTORS |
| /s/ Patrick O’Brien |
| Patrick O’Brien, |
Secretary
|
| Pasadena, California |
| January |
| 52 | |
20202022 PROXY STATEMENT Exhibit A
Exhibit A
Exhibit AARROWHEAD PHARMACEUTICALS, INC.
Amended and Restated
Bylaws of
Arrowhead Pharmaceuticals, Inc.
ARTICLE I
STOCKHOLDERS
Section 1.1Annual Meeting.
(a)General. The annual meeting of stockholders shall be held at the hour, date and place within or without the State of Delaware which is fixed by the Board of Directors, which time, date and place may subsequently be changed at any time by vote of the Board of Directors. If no annual meeting has been held for a period of thirteen (13) months after the corporation’s last annual meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these bylaws or otherwise, all the force and effect of an annual meeting. Any and all references hereafter in these bylaws to an annual meeting or annual meetings also shall be deemed to refer to any special meeting(s) in lieu thereof.
(b)Notice of Stockholder Business and Nominations.
(1) Nominations of persons for election to the Board of Directors and the proposal of other business to be considered by the stockholders may be brought before an annual meeting: (i) by or at the direction of the Board of Directors, or (ii) by any stockholder of the corporation who was a stockholder of record at the time of giving of notice provided for in this bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this bylaw as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii) shall be the exclusive means for a stockholder to bring nominations or business properly before an annual meeting (other than matters properly brought under Rule14a-8NON-EMPLOYEE (or any successor rule) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 1.1(b)(2) and (3) of this bylaw to bring such nominations or business properly before an annual meeting. In addition to the other requirements set forth in this bylaw, for any proposal of business to be considered at an annual meeting, it must be a proper subject for action by stockholders of the corporation under Delaware law.
(2) For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to clause (ii) of Article I, Section 1.1(b)(1) of this bylaw, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the corporation, (ii) have provided any updates or supplements to such notice at the times and in the forms required by this bylaw and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this bylaw. To be timely, a stockholder’s written notice shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to theone-yearDIRECTOR COMPENSATION PLAN anniversary of the preceding year’s annual meeting; provided, however, that in the event the annual meeting is first convened more than 30 days before or more than 60 days after such anniversary date, or if no annual meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the corporation not later than the close of business on the later of the 90th day prior to the scheduled date of such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as “Timely Notice”). Such stockholder’s Timely Notice shall set forth:
(A) as to each person whom the stockholder proposes to nominate for election or reelection as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);
(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below);
(C) (i) the name and address of the stockholder giving the notice, as they appear on the corporation’s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following
|
20202022 PROXY STATEMENT Exhibit A
information: (a)NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
The purpose of this Non-Employee Director Compensation Policy (this “Policy”) Arrowhead Pharmaceuticals, Inc. (the “Company”), is to provide a compensation package that enables the class or seriesCompany to attract and number of all shares of capital stockretain high-caliber directors and aligns their interests with the interests of the corporation which are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its affiliates or associates (as such terms are defined in RuleCompany’s stockholders.
12b-21. Eligibility promulgated under the Exchange Act), including any shares of any class or series of capital stock
The Policy applies to all members of the corporationCompany’s Board of Directors (the “Board”) who are not employees or officers of the Company or its subsidiaries. Directors who are employees or officers of the Company or its subsidiaries do not receive compensation for their service on the Board.
2. Director Pay Limit
On an annual basis, the Compensation Committee will retain an independent compensation consultant (the “Consultant”) to conduct an analysis and prepare a report on non-employee director compensation practices at a group of peer companies (the “Peer Companies”), which shall include an assessment of the mean per-director annual compensation package (including annual retainer, meeting fees, annual equity awards, etc.) paid by each of the Peer Companies (excluding directors who served less than a full year). The Peer Companies will be approved annually by the Compensation Committee based on a recommendation from the Consultant, and will include at least fifteen companies that are appropriate for the Company’s size (e.g., market capitalization, revenue, employee count) and competitive environment for executives and directors.
The value of the mean per-director compensation paid to the non-employee members of the Board (excluding for purposes of this calculation directors who serve less than the full year) each year as reported in the Company’s annual proxy statement may not exceed the mean per-director compensation package paid by the Peer Company representing the 60th percentile of the mean per-director compensation package paid by each of the Peer Companies, as reported by the Consultant. For 2022, this limit was determined to be $475,700.
Notwithstanding the forgoing, to the extent approved by a majority vote of the Company’s stockholders at the Company’s 2022 Annual Meeting (or such later date as determined by the Company), if, in any year, the Company’s 3-year total shareholder return (TSR) (as calculated by the Consultant) exceeds the 3-year TSR of the Peer Company representing the 60th percentile of the Peer Companies when ranked by 3-year TSR, the non-employee director pay limit described in this paragraph for the next following year shall be increased to correspond to the mean per-director compensation package paid by the Peer Company representing the percentile of the mean per-director compensation package paid by each of the Peer Companies that is equivalent to the percentile rank of the Company relative to the Peer Companies when ranked by 3-year TSR for such prior year.
3. Cash and Equity Retainers
On an annual basis, the Board, with the assistance of the Compensation Committee, will determine the value of cash and equity retainers paid to the non-employee members of the Board, which need not be the same for every director and which may take into account service as non-executive chair or lead independent director and/or service as chair or as a member on one or more committees of the Board; provided that the mean per-director compensation shall not exceed the limit on such Proposing Person or anycompensation as determined in accordance with the procedures described above.
4. Administration
The Board, with the assistance of its affiliates or associates has a right to acquire beneficial ownershipthe Compensation Committee, administers the Policy and may amend the Policy at any time in its sole discretion; provided, however, that the future, (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its affiliates or associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person, (y) whether or not such Synthetic Equity Interest is required toPolicy will be or is capable of being, settled through delivery of such shares and (z) whether or not such Proposing Person and/or, to the extent known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the corporation, (d) any rights to dividends or other distributionsreviewed on the shares of any class or series of capital stock of the corporation, directly or indirectly, owned beneficially by such Proposing Person that are separated or separable from the underlying shares of the corporation, and (e) any performance-related fees (other than an asset based fee) that such Proposing Person, directly or indirectly, is entitled to based on any increase or decrease in the value of shares of any class or series of capital stock of the corporation or any Synthetic Equity Interests (the disclosures to be made pursuant to the foregoing clauses (a) through (e) are referred to, collectively, as “Material Ownership Interests”) and (iii) a description of the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by any Proposing Person or any of its affiliates or associates with any other person for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the corporation;
(D) (i) a description of all agreements, arrangements or understandings by and among any of the Proposing Persons, or by and among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and
(E) a statement whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least the percentage of voting power of all of the shares of capital stock of the corporation reasonably believed by such Proposing Person to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder (such statement, the “Solicitation Statement”).
For purposes of this Article I of these bylaws, the term “Proposing Person” shall mean the following persons: (i) the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders’ meeting, and (ii) the beneficial owner(s), if different, on whose behalf the nominations or business proposed to be brought before a stockholders’ meeting is made. For purposes of this Section 1.1 of Article I of these bylaws, the term “Synthetic Equity Interest” shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase orso-called “stock borrowing” agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a) give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the corporation, (b) mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the corporation, (c) otherwise provide in any manner the opportunity to profit or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the corporation, or (d) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the corporation.
(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an annual meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be providedbasis in such notice pursuant to this bylaw shall be true and correct as of the record date for the meeting and as of the date that is ten business days prior to such annualconsultation with an independent compensation consultant.
Policy adopted on January 24, 2022
|
2020 PROXY STATEMENT Exhibit A
meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the corporation not later than the close of business on the fifth business day after the record date for the annual meeting (in the case of the update and supplement required to be made as of the record date), and not later than the close of business on the eighth business day prior to the date of the annual meeting (in the case of the update and supplement required to be made as of ten business days prior to the meeting).
(4) Notwithstanding anything in the second sentence of Article I, Section 1.1(b)(2) of this bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors of the corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 1.1(b)(2), a stockholder’s notice required by this bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the corporation.
(c) Other.
(1) Only such persons who are nominated in accordance with the provisions of this bylaw shall be eligible for election and to serve as directors and only such business shall be conducted at an annual meeting as shall have been brought before the meeting in accordance with the provisions of this bylaw. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this bylaw. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this bylaw, the presiding officer of the annual meeting shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this bylaw. If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this bylaw, such proposal or nomination shall be disregarded and shall not be presented for action at the annual meeting.
(2) Except as otherwise required by law, nothing in this Article I, Section 1.1 shall obligate the corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.
(3) Notwithstanding the foregoing provisions of this Article I, Section 1.1, if the proposing stockholder (or a qualified representative of the stockholder) does not appear at the annual meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the corporation. For purposes of this Article I, Section 1.1, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of the stockholders.
(4) For purposes of this bylaw, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.
(5) Notwithstanding the foregoing provisions of this bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this bylaw. Nothing in this bylaw shall be deemed to affect any rights of (i) stockholders to have proposals included in the corporation’s proxy statement pursuant to Rule14a-8 (or any successor rule) under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an annual meeting or (ii) the holders of any series of Preferred Stock to elect directors under specified circumstances.
Section 1.2 Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the corporation. Nominations of persons for election to the Board of Directors of the corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section 1.1(a) of these bylaws, in
|
2020 PROXY STATEMENT Exhibit A
which case such special meeting in lieu thereof shall be deemed an annual meeting for purposes of these bylaws and the provisions of Article I, Section 1.1(b) of these bylaws shall govern such special meeting.
Section 1.3 Notice of Meetings. Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, the written notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting. If mailed, such notice shall be deemed to be given when deposited in the mail, postage prepaid, directed to the stockholder at his/her address as it appears on the records of the corporation.
Section 1.4 Adjournments. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
Section 1.5 Quorum. At each meeting of stockholders, except where otherwise provided by law or the certificate of incorporation or these bylaws, the holders of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum. In the absence of a quorum, the stockholders so present may, by majority vote, adjourn the meeting from time to time in the manner provided in Section 1.4 of these bylaws until a quorum shall attend. Shares of its own stock belonging to the corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the corporation to vote stock, including but not limited to its own stock, held by it in a fiduciary capacity.
Section 1.6 Organization. Meetings of stockholders shall be presided over by the Chairman of the Board, if any, or in his/her absence by the Vice Chairman of the Board, if any, or in his/her absence by the President, or in his/her absence by a Vice President, or in the absence of the foregoing persons by a chairman designated by the Board of Directors, or in the absence of such designation by a chairman chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his/her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.
Section 1.7 Voting; Proxies. Except as otherwise provided in the certificate of incorporation or any amendment thereto, each stockholder entitled to vote at any meeting of stockholders shall be entitled to one vote for each share of stock held by him which has voting power upon the matter in question. Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for him by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with the Secretary of the corporation. Voting at meetings of stockholders need not be by written ballot and need not be conducted by inspectors unless the holders of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of all classes of stock entitled to vote thereon present in person or by proxy at such meeting shall so determine. At all meetings of stockholdersfor the election of directors a plurality of the votes cast shall be sufficient to electat which a quorum is present, all corporate actions to be taken by vote of the stockholders shall, unless otherwiseprovidedrequired by law or by the certificate of incorporation or these bylaws, be decided by the vote of shares representing a majority of the votes entitled to be cast by the holders of the outstanding shares of stock entitled to vote thereon present in person or by proxy at the meeting.
Section 1.8 Fixing Date for Determination of Stockholders of Record. In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty nor less than ten days prior to any other action. If no record date is fixed: (1) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; and (2) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
|
2020 PROXY STATEMENT Exhibit A
Section 1.9 List of Stockholders Entitled to Vote. The Secretary shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof and may be inspected by any stockholder who is present. Upon the willful neglect or refusal of the directors to produce such a list at any meeting for the election of directors, they shall be ineligible for election to any office at such meeting. The stock ledger shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list of stockholders or the books of the corporation, or to vote in person or by proxy at any meeting of stockholders.
Section 1.10 Action by Consent of Stockholders. Unless otherwise restricted by the Certificate of Incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.
ARTICLE II
BOARD OF DIRECTORS
Section 2.1 Number; Qualifications. The Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution of the Board of Directors. Directors need not be stockholders.
Section 2.2 Election; Resignation; Removal; Vacancies.The Board of Directors shall initially consist of the persons named as Directors by the Incorporator, and each Director so elected shall hold office until the first annual meeting of stockholders or until his/her successor is elected and qualified.At the first annual meeting of stockholders and at each annual meeting thereafter, the stockholders shall elect Directors each of whom shall hold office for a term of one year or until his/her successor is elected and qualified.At any meeting of stockholders for the election of Directors at which a quorum is present, each Director shall be elected by a majority of the votes cast; provided that, if the election is contested, the Directors shall be elected by a plurality of the votes cast. An election shall be contested if the number of nominees for Directorexceeds the number of Directors to be elected, as determined by the Board of Directors. For purposes of this Section 2.2, a majority of votes cast shall mean that the number of votes cast “for” a Director’s election exceeds the number of votes cast “against” that Director’s election (with abstentions and brokernon-votes not counted as a vote cast either “for” or “against” such Director’s election). Any Director may resign at any time upon written notice(including by electronic transmission) to the corporation; such resignation shall take effect upon delivery, unless the resignation specifies a later effective date or time or an effective date or time determined upon the happening of an event or events. Any vacancy occurring in the Board of Directors for any cause may be filled by a majority of the remaining members of the Board of Directors, although such majority is less than a quorum, or by apluralitymajority of the votes cast at a meeting of stockholders, and each Director so elected shall hold office until the expiration of the term of office of the Director whom he has replaced or until his/her successor is elected and qualified.
Section 2.3 Regular Meetings. Regular meetings of the Board of Directors may be held at such places within or without the State of Delaware and at such times as the Board of Directors may from time to time determine, and if so determined notices thereof need not be given.
Section 2.4 Special Meetings. Special meetings of the Board of Directors may be held at any time or place within or without the State of Delaware whenever called by the President, any Vice President, the Secretary, or by any member of the Board of Directors. Reasonable notice thereof shall be given by the person or persons calling the meeting, not later than the second day before the date of the special meeting.
Section 2.5 Telephonic Meetings Permitted. Members of the Board of Directors, or any committee designated by the Board, may participate in a meeting of such Board or committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this bylaw shall constitute presence in person at such meeting.
Section 2.6 Quorum; Vote Required for Action. At all meetings of the Board of Directors a majority of the directors then in office shall constitute a quorum for the transaction of business. Except in cases in which the certificate of incorporation or these
|
2020 PROXY STATEMENT Exhibit A
bylaws otherwise provide, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.
Section 2.7 Organization. Meetings of the Board of Directors shall be presided over by the Chairman of the Board, if any, or in his/her absence by the Vice Chairman of the Board, if any, or in his/her absence by the President, or in their absence by a chairman chosen at the meeting. The Secretary shall act as secretary of the meeting, but in his/her absence the chairman of the meeting may appoint any person to act as secretary of the meeting.
Section 2.8 Informal Action by Directors. Unless otherwise restricted by the certificate of incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.
ARTICLE III
COMMITTEES
Section 3.1 Committees. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it, but no such committee shall have the power or authority in reference to amending the Amended and Restated Certificate of Incorporation, as it may be amended from time to time (the “Certificate of Incorporation”) (except that any such committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of Preferred Stock adopted by the Board of Directors pursuant to Article Fourth of the Certificate of Incorporation, fix any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of the assets of the corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the corporation), adopting an agreement of merger or consolidation under Sections 251 or 252 of the General Corporation Law of the State of Delaware, recommending to the stockholders the sale, lease or exchange of all or substantially all of the corporation’s property and assets, recommending to the stockholders a dissolution of the corporation or a revocation of a dissolution, or amending these Bylaws; and unless the resolution or the Certificate of Incorporation expressly so provides, no such committee shall have the power or authority to declare a dividend, to authorize the issuance of stock, or to adopt a certificate of ownership and merger pursuant to Section 253 of the General Corporation Law of the State of Delaware.
Section 3.2 Committee Rules. Unless the Board of Directors otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board of Directors conducts its business pursuant to Article II of these Bylaws.
ARTICLE IV
OFFICERS
Section 4.1 Executive Officers; Election; Qualifications; Term of Office; Resignation; Removal; Vacancies. The Board of Directors shall choose a President and Secretary, and it may, if it so determines, choose a Chairman of the Board and a Vice Chairman of the Board from among its members. The Board of Directors may also choose one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers. Each such officer shall hold office until the first meeting of the Board of Directors after the annual meeting of stockholders next succeeding this election, and until his/her successor is elected and qualified or until his/her earlier resignation or removal. Any officer may resign at any time upon written notice(including by electronic transmission) to the corporation; such resignation shall take effect upon delivery, unless the resignation specifies a later effective date or time or an effective date or time determined upon the happening of an eventor events. The Board of Directors may remove any officer with or without cause at any time, but such removal shall be without prejudice to the contractual rights of such officer, if any, with the corporation. Any number of offices may be held by the same person. Any vacancy occurring in any office of the corporation by death, resignation, removal or otherwise may be filled for the unexpired portion of the term by the Board of Directors at any regular or special meeting.
|
2020 PROXY STATEMENT Exhibit A
Section 4.2 Powers and Duties of Executive Officers. The officers of the corporation shall have such powers and duties in the management of the corporation as may be prescribed by the Board of Directors and, to the extent not so provided, as generally pertain to their respective offices, subject to the control of the Board of Directors. The Board of Directors may require any officer, agent or employee to give security for the faithful performance of his/her duties.
ARTICLE V
STOCK
Section 5.1 Certificates. The Board may provide by resolution or resolutions that some or all of any or all classes or series of the stock of the Company shall be uncertificated shares. Certificates, if any, representing shares of stock of the Company will be in such form as is determined by the Board, subject to applicable legal requirements. Each such certificate shall be numbered and shall be signed by or in the name of the corporation by the Chairman or Vice Chairman of the Board of Directors, if any, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the corporation, certifying the number of shares owned by him in the corporation. Any of or all the signatures on the certificate may be a facsimile. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued by the corporation with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Records shall be kept of the amount of stock of the corporation issued and outstanding, the manner in which and the time when such stock was paid for, the respective names, alphabetically arranged, and the addresses, of the persons, firms or corporations owning of record the stock represented by certificates for stock of the corporation, the number, class and series of shares represented by such certificates, respectively, the time when each became an owner of record thereof, and the respective dates of such certificates, and in case of cancellation, the respective dates of cancellation.
Section 5.2 Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates. The corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the corporation may require the owner of the lost, stolen or destroyed certificate, or his/her legal representative, to give the corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.
Section 5.3 Transfers of Stock. Transfers of shares shall be made upon the books of the Company (i) only by the holder of record thereof, or by a duly authorized agent, transferee or legal representative and (ii) in the case of certificated shares, upon the surrender to the Company of the certificate or certificates for such shares. No transfer shall be made that is inconsistent with the provisions of applicable law. The person in whose name shares of stock stand on the books of the corporation shall be deemed the owner thereof for all purposes as regards the corporation. Whenever any transfer of shares shall be made for collateral security and not absolutely, such fact shall be so expressed in the entry of transfer if, when the certificate of certificates shall be presented to the corporation for transfer, both the transferor and the transferee request the corporation to do so.
Section 5.4 Regulations Concerning Transfer of Stock. The Board of Directors may make such rules and regulations as it may deem expedient, not inconsistent with these Bylaws, concerning the issue, transfer and registration of certificates for stock of the corporation. The Board of Directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and one or more registrars, and may require all certificates for stock to bear the signature or signatures of any of them.
ARTICLE VI
INDEMNIFICATION OF DIRECTORS,
OFFICERS, EMPLOYEES AND AGENTS
Section 6.1 Right to Indemnification. The corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative (a “proceeding”) by reason of the fact that he, or a person for whom he is the legal representative, is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise ornon-profit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses reasonably incurred by such person. The corporation shall indemnify a person in connection with a proceeding initiated by such person only if the proceeding was authorized by the Board of Directors of the corporation.
|
2020 PROXY STATEMENT Exhibit A
Section 6.2 Prepayment of Expenses. The corporation shall pay the expenses incurred in defending any proceeding in advance of its final disposition, provided, however, that the payment of expenses incurred by a director or officer in his/her capacity as a director or officer (except with regard to service to an employee benefit plan ornon-profit organization) in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the director or officer to repay all amounts advanced if it should be determined that the director or officer is not entitled to be indemnified under this Article VI or otherwise.
Section 6.3 Claims. If a claim for indemnification or payment of expenses under this Article VI is not paid in full within 90 days after a written claim therefor has been received by the corporation, the claimant may file suit to recover the unpaid amount of such claims and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such action the corporation shall have the burden of proving that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.
Section 6.4 Non-Exclusivity of Rights. The rights conferred on any person by this Article shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.
Section 6.5 Amendment or Repeal. Any repeal or modification of the foregoing provisions of this Article VI shall not adversely affect any right or protection of a director, officer or employee of the corporation in respect of any act or omission occurring prior to the time of such repeal or modification.
ARTICLE VII
MISCELLANEOUS
Section 7.1 Fiscal Year. The fiscal year of the corporation shall be determined by resolution of the Board of Directors.
Section 7.2 Seal. The Board of Directors may, but need not, adopt a corporate seal. If adopted, the corporate seal shall have the name of the corporation inscribed thereon and shall be in such form as may be approved from time to time by the Board of Directors.
Section 7.3 Waiver of Notice of Meetings of Stockholders, Directors and Committees. Any written waiver of notice, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in any written waiver of notice.
Section 7.4 Interested Directors; Quorum. No contract or transaction between the corporation and one or more of its directors or officers, or between the corporation and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof which authorizes the contract or transaction, or solely because his/her or their votes are counted for such purpose, if: (1) the material facts as to his/her relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or (2) the material facts as to his/her relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (3) the contract or transaction is fair as to the corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof, or the stockholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee, which authorizes the contract or transaction.
Section 7.5 Form of Records. Any records maintained by the corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs, or any other information storage device, provided that the records so kept can be converted into clearly legible form within a reasonable time. The corporation shall so convert any records so kept upon the request of any person entitled to inspect the same.
|
2020 PROXY STATEMENT Exhibit A
Section 7.6 Amendment of Bylaws. These Bylaws may be altered or repealed, and new bylaws made, by the Board of Directors, but the stockholders may make additional bylaws and may alter and repeal any bylaws whether adopted by them or otherwise.
* * *
|
ARROWHEAD PHARMACEUTICALS, INC. 177 EAST COLORADO BLVD, SUITE 700 PASADENA, CA 91105
VOTE BY INTERNET
Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above
Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before thecut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.
During The Meeting - Meeting—Go to www.virtualshareholdermeeting.com/ARWR2020 ARWR2022
You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions.
VOTE BY PHONE -PHONE—1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time the day before thecut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: E88884-P32218
D66586-P65348 KEEP THIS PORTION FOR YOUR RECORDS
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY
ARROWHEAD PHARMACEUTICALS, INC.
The Board of Directors recommends you vote FOR ALL the following director nominees: For All Withhold All Except For All following:
1. Election of Directors
Nominees: 01) Christopher Anzalone 02) Marianne De Backer 03) Mauro Ferrari 04)For Against Abstain
1a. Douglass Given 05) Michael S. Perry 06) William Waddill To withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the nominee(s) on the line below. The Board of Directors recommends you vote FOR For Against Abstain proposals 2, 3, and 4:
1b. Michael S. Perry 2. To approve, in an advisory(non-binding) vote, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation 1c. Christopher Anzalone S-K, including the compensation tables and narrative discussion.
1d. Marianne De Backer 3. To approve an amendment to the Company’s Amended and Restated Bylaws to implement a majority vote standard in uncontested elections of directors.Arrowhead Pharmaceuticals, Inc. Non- Employee Director Compensation Plan.
1e. Mauro Ferrari 4. To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2020. For Against Abstain2022.
1f. Adeoye Olukotun
1g. William Waddill NOTE: Such other business as may properly come before the
meeting or any adjournment thereof.
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.
Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
The Notice and Proxy Statement and Form10-K are available at www.proxyvote.com. E88885-P32218
D66587-P65348
ARROWHEAD PHARMACEUTICALS, INC. Annual Meeting of Stockholders March 19, 202017, 2022 10:00 AM, PT
This proxy is solicited by the Board of Directors
The stockholder(s) hereby appoint(s) Christopher Anzalone and Patrick O’Brien or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of Common Stock of ARROWHEAD PHARMACEUTICALS, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 10:00 AM, PT on March 19, 2020,17, 2022, online at WWW.VirtualShareholderMeeting.com/ARWR2020,www.virtualshareholdermeeting.com/ARWR2022, and any adjournment or postponement thereof.
This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors’ recommendations.
Continued and to be signed on reverse side
